Annual Report 2006/2007
Department of Oncology
August 14, 2007.
Chair: Gerald Batist, MD
Prepared by Gayle A. Shinder, PhD
Department of Oncology Annual Report 2006/2007
Message from the Chair
The 2006/2007 academic year was a year of growth for...
Department of Oncology Annual Report 2006/2007
Several of the Department’s faculty members were the recipients of awards a...
Department of Oncology Annual Report 2006/2007
winners of the “Oncology Cup” which is now displayed in the Board Room of t...
Department of Oncology Annual Report 2006/2007
Ala-Eddin Al Moustafa
1. Research Grants (new and ongoing)
1- CIHR team gra...
Department of Oncology Annual Report 2006/2007
- The European Journal of Oral Sciences
- Future Medicine
- Biotechniques
4...
Department of Oncology Annual Report 2006/2007
Principal Investigator: P.J.Allison
Co-investigators: L.J.Edgar, J.S.Feine,...
Department of Oncology Annual Report 2006/2007
My role: Supervisor
Project title: An investigation of nutrition in the nat...
Department of Oncology Annual Report 2006/2007
Dr William Foulkes (Department of Human Genetics, McGill)
Dr Sabine Mai (Un...
Department of Oncology Annual Report 2006/2007
3. Research Training: undergraduate students, graduate students, postdocs/f...
Department of Oncology Annual Report 2006/2007
6. Hospital Activities
Raquel Aloyz is in charge of supervising the in vitr...
Department of Oncology Annual Report 2006/2007
2. Member of the Surgical Oncology Residency Training Committee
Mark Basik
...
Department of Oncology Annual Report 2006/2007
5. Peer-Reviewed Abstracts
Hassan S., Salvucci O, Baccarelli A, Basik M. St...
Department of Oncology Annual Report 2006/2007
Gerald Batist
1. Research grants (new and ongoing)
2002-2008 Canadian Insti...
Department of Oncology Annual Report 2006/2007
-Editorial Board, Journal of Liposome Research, Marcel Dekker
-Editorial Bo...
Department of Oncology Annual Report 2006/2007
2007 Chicago, ASCO, presented poster, abstract title: “Ratiometric dosing o...
Department of Oncology Annual Report 2006/2007
Analyses of brain-tropism of MHV in Ceacam1-/- targeted mice. Dr. Susan Wei...
Department of Oncology Annual Report 2006/2007
Cancer Research Society Inc., Involvement of mouse biliary glycoproteins (C...
Department of Oncology Annual Report 2006/2007
Sarah Leblanc 2007-present, M.Sc. (2009)
Post-Doctoral Fellows
Anne-Laure N...
Department of Oncology Annual Report 2006/2007
Member of the “Prix de la Recherche” committee for ACFAS, 2004-06
Canadian ...
Department of Oncology Annual Report 2006/2007
Hyperproliferative Corneal Epithelium Expresses Proinflammatory Molecules T...
Department of Oncology Annual Report 2006/2007
b. Mechanism of Action of the Adenovirus Death Protein E4orf4 (Main applica...
Department of Oncology Annual Report 2006/2007
6. Conference Organization
Organizer and session chair, DNA Tumor Virus Mee...
Department of Oncology Annual Report 2006/2007
2. Scientific Reviews: Editorial Boards and Journal Reviews
Journal Reviews...
Department of Oncology Annual Report 2006/2007
GRISIM: Groupe de recherche interuniversitaire en soins infirmiers de Montr...
Department of Oncology Annual Report 2006/2007
2. Teaching and Research Training
PhD Students and Postdocs
Shuling Chen Sp...
Department of Oncology Annual Report 2006/2007
Palliative Medicine, 1996, 97, 98, 99, 2001, 2006
Journal of Pain and Sympt...
Department of Oncology Annual Report 2006/2007
6. Invited Presentations and Workshops (National and International) and Pee...
Department of Oncology Annual Report 2006/2007
7. Hospital Activities
Encompassed within responsibilities with McGill.
McG...
Department of Oncology Annual Report 2006/2007
Présidente d’atelier, Soins palliatifs, Congrès international de droit médi...
Department of Oncology Annual Report 2006/2007
Membre délégué au Conseil d’administration de l’Association canadienne de s...
Department of Oncology Annual Report 2006/2007
The major goal of this study is to determine if alterations in receptor tyr...
Department of Oncology Annual Report 2006/2007
Title of Grant: Risk factor analysis of hereditary breast and ovarian cance...
Department of Oncology Annual Report 2006/2007
2. Research Training: undergraduate students, graduate students, postdocs/f...
Department of Oncology Annual Report 2006/2007
5. Invited Presentations and Workshops (National and International)
a) Inte...
Department of Oncology Annual Report 2006/2007
Eduardo Franco
1. Summary of New and Ongoing Research
As PI:
• Antioxidant ...
Department of Oncology Annual Report 2006/2007
• Prognostic value of clinical correlates of cancer cachexia: A prospective...
Department of Oncology Annual Report 2006/2007
International Activities:
• PI of the Ludwig-McGill Cohort Study of the Nat...
Department of Oncology Annual Report 2006/2007
• L Tomita. Diet, serum micronutrients and risk of cervical neoplasia. Ongo...
Department of Oncology Annual Report 2006/2007
Faculty evaluations
• Fred Hutchinson Cancer Research Center, Division of P...
Department of Oncology Annual Report 2006/2007
• Member, Ad hoc Meeting of experts on surveillance of HPV-associated disea...
Department of Oncology Annual Report 2006/2007
• Chair and Speaker, “Prevention of cervical cancer: New paradigms”, Lectur...
Department of Oncology Annual Report 2006/2007
• “Issues in planning screening in the era of HPV vaccination” Lecture, 2nd...
Department of Oncology Annual Report 2006/2007
• “Vacinação Contra a Infecção pelo HPV: O novo Paradigma da Prevenção do C...
Department of Oncology Annual Report 2006/2007
• Speaker, Meet the Experts Session: Putting Science into Practice, 23rd In...
Department of Oncology Annual Report 2006/2007
• “Molecular epidemiology of HPV infection: new approaches” Roundtable
pres...
Department of Oncology Annual Report 2006/2007
• “HPV vaccination and screening: The need for synergy in cervical cancer p...
Department of Oncology Annual Report 2006/2007
• Sichero L, Ferreira S, Trottier H, Ferenczy A, Franco EL, Villa LL. High ...
Department of Oncology Annual Report 2006/2007
Consultancies to the private sector:
• Technical Advisory Committee, Glaxo ...
Department of Oncology Annual Report 2006/2007
3. Construction of major facilities or major equipment grants
As Head of Ra...
Department of Oncology Annual Report 2006/2007
Canadian Medical Association Journal
Clinical and Investigative Medicine
Ex...
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Annual Report 2006/2007 Department of Oncology
Upcoming SlideShare
Loading in...5
×

Annual Report 2006/2007 Department of Oncology

4,873

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
4,873
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Annual Report 2006/2007 Department of Oncology

  1. 1. Annual Report 2006/2007 Department of Oncology August 14, 2007. Chair: Gerald Batist, MD Prepared by Gayle A. Shinder, PhD
  2. 2. Department of Oncology Annual Report 2006/2007 Message from the Chair The 2006/2007 academic year was a year of growth for the Department of Oncology as we welcomed several new faculty members: In July 2006 the Department welcomed Dr. Carmela Pepe (Assistant Professor, Medical Oncology), Dr. Polymnia Galiatsatos (Associate Member, Medical Oncology), Dr. Fabio Cury (Assistant Professor, Radiation Oncology) and Dr. Mary Ellen MacDonald (Faculty Lecturer, Psychosocial Oncology Program). Dr. MacDonald’s position has recently been converted to an Assistant Professor. November 2006 heralded the arrival of Dr. Esther Shirrmacher (Assistant Professor, Experimental Therapeutics & Pharmacology), Dr. Linda Ofiara (Associate Member, Medical Oncology) and Dr. Robert Turcotte (Associate Member, Surgical Oncology. Finally, in February 2007 Dr. Janusz Rak came on board as an Associate Member, Hematology/Oncology while in April Dr. Nada Jabado became an Associate Member, Pediatric Oncology. In June 2006, Dr. Antonis Koromilas was promoted to full professor, and Dr. Gerald Batist was renewed as Chair of the Department of Oncology for a second 5 year term. Also in 2006, Dr. Carmen Loiselle was appointed Director of the Oncology Nursing Program. The goals of this Program are: • To provide a platform for academic and professional activities and exchanges among nurse researchers, undergraduate and graduate students, nurse managers, clinical specialists and nursing staff. • To encourage trans-disciplinary collaboration across cancer-related fields such as epidemiology, medicine, nursing, psychology, occupational therapy, physiotherapy and social work. • To increase the visibility of oncology nursing at McGill University, its affiliated health centers and abroad. The academic year also saw the departures of Dr. Brian Leyland-Jones, former Oncology Chair, who became Director of the Winship Cancer Institute at Emory University in Atlanta, Dr. Wahbi Hammouda who joined Sunnybrook Health Sciences Centre in Toronto, and Dr. Julio Guerra who has retired. The Department of Oncology administrative offices have also undergone some changes. Following the departure of Anna Ciarciello (Accounts Administrator & Visiting Professor Program Coordinator), Joanne Miller temporarily took over that role along with her duties as RUIS Liaison. As of March 2007, Winie Celestin has taken over those duties as Joanne Miller has moved to the Faculty of Management. In November 2006 Christine Talbot relinquished her role in maintaining the Department of Oncology website so that she could focus her attention on completing her final year as an undergraduate student. Kingsley Cheung took over those duties until June 2007 when Christine Talbot resumed website maintenance for the summer months. 2
  3. 3. Department of Oncology Annual Report 2006/2007 Several of the Department’s faculty members were the recipients of awards and honours: Dr. Paul Allison was the recipient of the Howard Katz Award for Excellence in Teaching; Dr. Dawn Anderson was the recipient of the Inaugural Hingston Grant for Development of Medical Leadership; Dr. Nicole Beauchemin and Dr. Philip Gordon each received the Faculty of Medicine “Faculty Honour List for Educational Excellence” 2007; Dr. Martin Chasen and Dr. Thierry Muanza were each recipients of the Simone & Morris Fast Award; Dr. Fabio Cury was given the MGH 175th Anniversary Award; Dr. Eduardo Franco was awarded the “Ambassadeur de Montréal”, a prize by the Montreal Congress Centre; the Phil Gold Chair in Medicine was established in November 2006; Dr. Stephen Liben received the Service Award – Commander Palliative Care Presentation from The Military & Hospitaller Order of St. Lazarus and was also awarded First Prize - Royal Society of Medicine Book Awards, for the Oxford Textbook of Palliative Care for Children (Goldman, Hain, Liben eds); Dr. Ervin Podgorsak was the recipient of the Coolidge Award from the American Association of Physicists in Medicine; Dr. Stephane Richard was awarded the Prix d’excellence en recherche from the Conseil des gouverneurs de l'Hôpital general juif; Dr. George Shenouda received The Olive Williamson Award and was placed on the Faculty of Medicine’s Honour List for Educational Excellence; Dr. Michel Tremblay was elected a Fellow of the Royal Society of Canada; and Dr. Te Vuong was awarded both the RVH centennial Research Grant Award as well as the Howard W Pillow memorial Research Award. This year’s FRSQ salary award recipients were Dr. Stephane Richard (Chercheur Nationaux) Dr. William Foulkes (Chercheur Nationaux) and Dr. Marc Tischkowitz (Chercheur-boursier clinicien Junior 1) while Dr. Te Vuong was the recipient of a CIHR salary award. Through the efforts of Dr. Lawrence Panasci, Bayer Canada Inc. has given the Department of Oncology $40,000/yr for two years to award a Bayer Fellowship in Oncology. The first recipient of this award is Dr. Cristiano Ferrario who is working on combining new agents with traditional chemotherapy and integrating translational research in search of predictors of response. The 2006 Oncology Summer Scholarship Program was awarded to 1. Michael Dunn under the direction of Dr. Raquel Aloyz, for the research "The expression of the DNA repair proteins XPD and Xrcc3 as indicators of platinum resistance in ovarian cancer" and 2. Wenyong Tong under the direction of Dr. Uri Saragovi, for the research "Structure and Activity relationship between Ganglioside CG2 and its ligands”. This year’s Dept. of Oncology Retreat was held November 16, 17, 2006 at Le Sporting Club du Sanctuaire. In addition to the many interesting presentations covering basic, clinical and psychosocial research in oncology, attendees were encouraged to exercise and de-stress by participating in a floor hockey tournament. The Red Team were the 3
  4. 4. Department of Oncology Annual Report 2006/2007 winners of the “Oncology Cup” which is now displayed in the Board Room of the Gerald Bronfman Centre along with a photograph of the winners. The Montreal Centre for Experimental Therapeutics in Cancer (MCETC) held its Fourth Annual Meeting on October 26, 27, 2006. Over 150 researchers and students from across Quebec listened to presentations focusing on discoveries currently being tested in the clinic as well as those which are approaching clinical trials. The 16th International Congress on Care of the Terminally Ill took place at the Palais des Congrès September 26-29, 2006. Congress Chair, Dr. Anna Towers, and members of the Executive Committee, Program Committee, Program Advisors and the Congress Secretariat, worked diligently to put together a diverse program touching on such topics as pediatric palliative care, complementary and alternative therapies, spirituality and hospice and palliative care services. The committee is now hard at work organizing The 17th International Congress on Care of the Terminally Ill in 2008. After being on hiatus, the Palliative Care Research Newsletter resumed in Fall 2006 with a brand new look. Edited by Dr. Gayle A. Shinder, the newsletter featured the research studies being conducted by members of the group, in areas such as Quality of Life, Networking, Anorexia Cachexia, Pain, Lymphedema, Palliative Care Services, Family Caregiving and Pediatric Palliative Care, In addition, the newsletter featured sections on Honours and Awards, Teaching and Training and the Psychosocial Oncology Option. The Visiting Professors in Oncology Program has been very active this year with presentations covering areas such as adjuvant endocrine treatment of breast cancer, radiation therapy, palliative care, cardiac side effects from cancer treatment and psychosocial issues in oncology patients. Following the Programme Québecois de lutte contre le cancer evaluations of Sections A to F in the Spring of 2006, Department of Oncology clinicians in the various tumour groups worked with their respective hospital-based inter-disciplinary teams to draft Section G of the document in preparation for evaluation of Quebec Supraregional status. To date, several tumour site teams have already undergone the site visit. The process will be continuing into the Summer/Fall of 2007. The Table d’oncologie of RUIS McGill continued to meet on a monthly basis, tackling a range of policy and service issues related to the RUIS. Gerald Batist, MD 4
  5. 5. Department of Oncology Annual Report 2006/2007 Ala-Eddin Al Moustafa 1. Research Grants (new and ongoing) 1- CIHR team grant in HPV infection and associated diseases Source: CIHR Dollars Awarded: $ 508,218 per annum Dates of Approved Project: Oct.07 – Oct. 12 Role: Co-Applicant 2- Regulation of Basic Helix-Loop-Helix Transcription Factors in Human Colorectal Carcinogenesis Source: The National Colorectal Cancer Campaign Dollars Awarded: $33,900 per annum Dates of Approved Project: Jan. 06 – Jan. 07 Role: P.I 3- HPV, ErbB-2 and D-type cyclin interactions in vivo and in vitro studies. Source: CIHR Dollars Awarded: $90,646 per annum Dates of Approved Project: Oct. 04 – Oct. 07 Role: P.I 2. Presentations April 14-18, 2007 – Poster Presentation: AACR Annual Meeting, Los Angeles, CA, USA Sept. 2-8, 2006 – Oral Presentation: 9th International Conference of Drug and Gene- based Therapeutics, island of Crete, Greece Aug. 3, 2006 – Oral Presentation: Centre for cell Biology & Cancer Research, Albany, New York, USA 3. Journal reviewer - Cancer research - Clinical Cancer Res. - Carcinogenesis - Molecular Cancer Therapeutics - International Journal of Cancer - The Lung Cancer Journal 5
  6. 6. Department of Oncology Annual Report 2006/2007 - The European Journal of Oral Sciences - Future Medicine - Biotechniques 4. Provincial, National and International Committees and Panels 2006-2007 Member of Hong Kong University grants committee, China 5. Professional Societies 2007- Member, National Arab American Medical Association (NAAMA) Paul Allison 1. Summary of New and Ongoing Research During the last year I have continued with two major projects involving my principal area of interest – the psychosocial elements of head and neck cancer. The first is a randomised trial investigating the effect of a psycho-educational intervention on H&N cancer patients with medium of high levels of psychological distress. The second project is an investigation of the interaction of psychosocial and biological factors along the life course in the aetiology of H&N cancer. This latter project involves collaborating sites in Brazil, South Africa and India. With respect to the last country, we were awarded a MISRI grant by McGill to help our collaboration and piloting of the work in that country. 2. Research grants (new and ongoing) Principal Investigator: P.J.Allison Co-investigators: E.L.Franco, R.Fuhrer, G.Humphris, B.F.Nicolau, A.Sacker Granting organisation: Canadian Institutes of Health Research Dates: Oct 2004 – Sept 2007 Amount: $434,063 Project title: The life course approach to the aetiology of squamous cell carcinoma in the upper aerodigestive tract 6
  7. 7. Department of Oncology Annual Report 2006/2007 Principal Investigator: P.J.Allison Co-investigators: L.J.Edgar, J.S.Feine, E.L.Franco, B.F.Nicolau, R.D.Rajan Granting organisation: Canadian Institutes of Health Research Dates: April 2005 – March 2009 Amount: $471,139 Project title: A randomised controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer PI: B. Nicolau Co-investigators: P.J.Allison, R. Burk, F. Coutlée, E. Franco, G. Humphris, J. O’Loughlin, A. Sacker, N. Schlecht Granting organization: Canadian Institutes of Health Research Dates: October 2006 – September 2010 Amount: $476,000 Project title: The life course approach to studying the etiology of head and neck cancer: HeNCe life study PI: P.J.Allison Co-investigators: B. Nicolau, E.L Franco, V.I. Varghese & G. Netuveli Granting organization: McGill India Strategic Research Initiative Dates: October 2006 – October 2007 Amount: $16,396 Project title: International multi-centre study of the aetiology of upper aerodigestive tract cancer investigating environmental and social factors during the life span: the HeNCe Life Study 3. Research Training: undergraduate students, graduate students, postdocs/fellows Student: Katia Muller Degree: Postdoctoral student Dates: September 2006 – present 7
  8. 8. Department of Oncology Annual Report 2006/2007 My role: Supervisor Project title: An investigation of nutrition in the natural history of pre-oral- cancerous lesions Sponsorship: Faculty of Dentistry scholarship Student: Larissa Vilela Degree: PhD Dates: January 2005 – present My role: Supervisor Project title: An investigation of the predictive value of sense of coherence on survival in people with head and neck cancer Sponsorship: CIHR research grant 4. Scientific Reviews: Editorial Boards and Journal Reviews Editorial Board - Journal of Dental research 5. Research Advisory Work for National and International Organizations NCIC operating grant review panel K – Supportive Care, Palliative Care and Psychosocial Issues (Oct 2005 – present day) National Institutes of Dental and Craniofacial Research, NIH, Special grant panel (June 2006 & May 2007) 6. Invited Presentations and Workshops (National and International) P.J.Allison: How to improve quality of life in head and neck cancer patients. Presented to the 5th International Workshop on Quality of Life in Heand & Neck Cancer, Liverpool, November 2006 Raquel Aloyz 1. Summary of New and Ongoing Research (Collaborations) Dr Sylvain Martel (Ecole Polythechnique de Montreal) Dr Lawrence Panasci (Department of Oncology, McGill) Dr Ester Schirrmacher (Department of Oncology, McGill University) Member of the CLL Canadian Network, funded in 2005. 8
  9. 9. Department of Oncology Annual Report 2006/2007 Dr William Foulkes (Department of Human Genetics, McGill) Dr Sabine Mai (University of Manitoba, Winnipeg) Dr Minna Tanner (University of Tampere, Finland) 2. Research grants (new and ongoing) Grant Title: Mechanisms of Dasatinib sensitization to standard therapy in chronic lymphocytic leukemia Agency: CIHR Type: Operating Grant Period: 2007-2009 Role: Principal Investigator Co applicants: None Project Title: "Role of BRCA1 and BRCA2 in breast carcinogenesis" Agency: SDM- Jewish General Hospital Foundation. Weekend to End Breast Cancer Award Period: 2006-2007 Role:Principal Investigator Co applicants: None Grant Title: Towards the biological treatment of BRCA1-related breast cancer: EGF, EGFR and tyrosine kinase inhibitors Agency: Breast Cancer Research Alliance Type: Research Operating Grant Period: 2006-2009 Role: Co-Investigator Project Title: Inhibition of DNA-PK to sensitize CLL lymphocytes to chlorambucil. Agency: Leukemia & Lymphoma Society of America Type: Translational Research Grant Period: 2005-2008 Role: Co-Principal Investigator 9
  10. 10. Department of Oncology Annual Report 2006/2007 3. Research Training: undergraduate students, graduate students, postdocs/fellows Graduate Students: Michael Dunn (Master Student) Tayma Khalil (Master Student, Co-Supervisor) Post Doctoral Fellow: Carolyn Annette Holmann 4. Invited Presentations and Workshops (National and International) Canadian CLL Symposium. “DNA Repair in Chronic Lymphocytic Leukemia” Inn at the Forks, Winnipeg, Manitoba, November 12 & 13, 2006 5. Peer-Reviewed Abstracts #3475 Determining the effect of estrogen metabolites on BRCA1-allelic imbalance in normal breast cells heterozygous for BRCA1 mutations . Revital Bar Sade-Bruchim, Tayma Khalil, Louise Quenneville, William Foulkes, George Chong, Raquel S. Aloyz. Lady Davis Inst. for Medical Research, Montréal, PQ, Canada Poster Session. Board#: 22. American Association For Cancer Research, Centennial Meeting, 14-18 April 2007 #4753 Dasatinib sensitizes chronic lymphocytic leukemia lymphocytes to chemotherapeutic agents Anne-Christine Goulet, Lilian Amrein, Michael Dunn, Raquel Aloyz, Lawrence C. Panasci. Jewish General Hospital, Montréal, PQ, Canada Board#: 6. American Association For Cancer Research, Centennial Meeting, 14-18 April 2007 The p75 neurotrophin receptor regulates activity-dependent axon competition by antagonizing TrkA-mediated Ras-Raf-MAPK signaling Singh K (Singh, K.), Kramer B (Kramer, B.), Lin D (Lin, D.), Aloyz R (Aloyz, R.), Kaplan D (Kaplan, D.), Miller F (Miller, F.) International Journal Of Developmental Neuroscience 24 (8): 578-579 DEC 2006 Inhibition of DNA repair vis-a-vis resistance in chronic lymphocytic leukemia Amrein L, Loignon M, Aloyz R, et al.. EJC SUPPLEMENTS 4 (12): 152-152 498 NOV 2006 10
  11. 11. Department of Oncology Annual Report 2006/2007 6. Hospital Activities Raquel Aloyz is in charge of supervising the in vitro correlations in a clinical protocol sponsored by Novartis. Clinical protocol (A phase I-II trial of Gleevec in combination with chlorambucil in previously treated chronic lymphocytic leukemia (CLL) patients) sponsored by Novartis. Three hospitals participate in this trial (Jewish General Hospital, Hopital Notre-Dame, CHUM, Hopital Charles Lemoyne). Dawn Anderson 1. Summary of New and Ongoing Research 1. PI at the Ville Marie Breast clinic for the NEOCAN study, a multicentered Canadian research protocol utilizing neo-adjuvant Letrozole in breast cancer. 2. Co-Investigator at St. Mary’s for three research protocols involving analysis of hereditary breast cancer.(Dr. W Foulkes PI on all 3). 3. Co-Investigator at St. Mary’s for breast cancer stem cell project (Dr. Danuta Balicki PI) 2. Hospital Activities 1. Surgical Grand Rounds at SMH including advising the Chief resident on appropriate topics. 2. Recording secretary for the St. Mary’s Interdisciplinary Thyroid Rounds, where patients are presented pre and/or post operatively to a team made up from surgery, endocrinology, pathology, medical oncology and nuclear medicine. 3. Lower GI Tumor Board at the Montreal General Hospital. 4. St. Mary’s weekly Tumor Board. 5. Ville Marie Breast Cancer weekly Clinico-Pathology Rounds . 6. Postgraduate Surgical Education Coordinator for St. Mary’s Hospital- supervising, advising and evaluating the surgical residents, family medicine residents and surgical oncology fellows who rotate through the surgical service at SMH, as well as mentoring ICM students to review case reports and supervising residents and students who choose electives at SMH 7. Formal small group teaching to ICM students. 3. Involvement in continuing education activities 1. Member of the General Surgery Residency Committee. 11
  12. 12. Department of Oncology Annual Report 2006/2007 2. Member of the Surgical Oncology Residency Training Committee Mark Basik 1. Summary of New and Ongoing Research All Ongoing i. Discovery and validation of amplicons in colon and breast cancer ii. Discovery of novel tumor suppressor genes in breast cancer iii. mechanisms of resistance to trastuzumab iv. Paracrine factors in stroma-tumor cell interactions v. clinical serum/plasma proteomics 2. Research grants (new and ongoing) i. Quebec Breast Cancer Foundation $ 138 000/year 2004-2007 « The Discovery of Novel Tumor Suppressor Genes in Breast Cancer ». Multi-investigator grant (total amount $1,500,000/3 years), PI : M. Basik; co-applicants : P. Tonin, S.Mader, C.Rancourt ii. Cancer Research Society $ 60000/year 2006-8 «DARPP32 in resistance to trastuzumab in breast cancer », PI : M. Basik, co-applicant : W. Miller. iii.Clinical Proteomics in breast cancer $ 70000/yr 2006-7. Weekend to end breast cancer 3. Research Training: undergraduate students, graduate students, postdocs/fellows Students: Saima Hassan, Adbel Hosein, Sophie Hamel Postdocs: Adriana Aguilar, Aline Mamo 4. Invited Presentations and Workshops (National and International) “Discovering and validating novel targets and markers in breast and colon cancer”. Seminar, Dept Anatomy and Cell Biology, McGill University. October 25, 2006 “ Breast cancer update: prevention, detection and treatment”, and “Workshop on genetic testing and counseling in breast cancer”. Presented at the Annual Refresher Course for Family Physicians, McGill University Faculty of Medicine, November 28th 2006, Hotel Bonaventure Hilton. “Cancers Héréditaires: sein et côlon”. Led workshop seminar at the Annual Congress of the Association Québécoise de Chirurgie. La Malbaie, Qc, May 31, 2007. 12
  13. 13. Department of Oncology Annual Report 2006/2007 5. Peer-Reviewed Abstracts Hassan S., Salvucci O, Baccarelli A, Basik M. Stromal cell derived factor (SDF)-1: predictive marker of distant metastasis and poorer survival in breast cancer. Clinical and Investigative Medicine Vol. 29 (4), Aug 2006: 268. Mamo A., Cavallone L., Ferrario C., Rancourt C. and Basik M. Genomic alterations as a guide to the discovery of novel therapeutic targets in breast cancer. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Cavallone L., Mamo A., Basik M. and Tonin P.An integrated genomics approach towards the identification of tumor suppressor gene candidates through nonsense- mediated mRNA decay inhibition of breast cancer cell lines. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Hassan S., Salvucci O, Baccarelli A, Basik M. Stromal cell derived factor (SDF)-1: predictive marker of distant metastasis and poorer survival in breast cancer. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Aguilar-Mahecha A, Cantin C, Deneault JS, Wu M, Huneau MC, O'Connor-McCourt M, Nantel A, Basik M. Optimization of reverse phase protein microarrays for blood biomarker validation . Presented at 5th Annual World Congress Human Proteome Organization, Long Beach, CA, Oct 2006 Hamel S, Wu M, Basik M. Molecular determinants of resistance to trastuzumab in breast cancer. Abstract at the Annual Meeting of the American Association for Cancer Research, Los Angeles April 2007. 6. Hospital Activities Medical Director of the Breast Cancer Inter-Disciplinary Team, Segal Cancer Centre, Jewish General Hospital Co-Director of Surgical Grand Rounds, Jewish General Hospital 7. Involvement in the community Speaker at the Weekend to End Breast Cancer, August 2006 13
  14. 14. Department of Oncology Annual Report 2006/2007 Gerald Batist 1. Research grants (new and ongoing) 2002-2008 Canadian Institutes of Health Research, partnership with FRSQ, Montreal Centre for Experimental Therapeutics in Cancer, Strategic Training Program, G. Batist - P.I., Co-Invs. W. Miller, M. Alaoui-Jamali, J. Galipeau, C. Rancourt, et al. 6yrs., average operating $262,500 (Total : $1,455,000+ $120,000 FRSQ) 2003-2006 Canadian Institutes of Health Research, Characterization of the active site in gamma-glutamylcysteine synthetase and development of its novel inhibitors through molecular modeling, site-directed mutagenesis and synthetic chemistry, Operating Grant, G. Batist-P.I., Co-Inv.- JH Wu, $109,220/yr, 3yrs. 2003-2007 Canadian Breast Cancer Research Alliance, P.I.-Ronal S.Foley, McMaster Univeristy, Co-Principals: Mark Levine, Jonathan Bramson, Gerald Batist et al, Therapeutic cell genetic immunization for breast cancer, CBCRA Translational Acceleration Research Grant, 4yr award/2003-2007, Total amount: $1,717,848 2005-2007 The Cancer Research Society, Operating grant, Functional analysis of novel potential chemopreventive agents. G. Batist-P.I., Co-Inv.- JH Wu, Total amount: $120,000 04/2006-03/2009 Canadian Institutes of Health Research, Regulation of glutathione and related enzymes: dissection of the Nrf-2 master regulator and generation of novel potential chemopreventive molecules (renewal) $100,655/yr 09/2006-08/2008 The Cancer Research Society, research grant, Cullin3 regulates the proliferation of breast cancer cells, a potential novel target for therapeutic intervention, Co-PI/ Weimin Miao, 2yrs - $60,000 per annum ($120,000) 08/2006-03/2007 Canadian Institutes of Health Research, GD2 gangliosides and Small Cell Lung Cancer, one year (Aug.1/06 to July 31/07). Partners: Mimetogen Pharmaceuticals Inc. $250,000(non-renewable) 07/2007-2010 Canadian Institutes of Health Research, EphB2, a novel target for gamma- secretase inhibitors (GSIs) in cancer therapy, P.I.- G. Batist, Co-PI: M. Kandouz, $150,000 per annum ($450,000) 2. Research Training: undergraduate students, graduate students, postdocs/fellows Andrew Bier, Ph.D. Student, 2001- Mustapha Kandouz, Ph.D. Student, 2001- Khadijia Haidara, Ph.D. Student, 2003- 3. Scientific Reviews: Editorial Boards and Journal Reviews -Associate Editor, J. Cellular Pharmacology, Springer-Verlag 14
  15. 15. Department of Oncology Annual Report 2006/2007 -Editorial Board, Journal of Liposome Research, Marcel Dekker -Editorial Board, Molecular Cancer Therapeutics, AACR -Member, Montreal Gazette "Board of Contributors" -Ad hoc reviews for: Cancer Research, Journal of Biological Chemistry, Biochemical Pharmacology, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology 4. Research Advisory Work for National and International Organizations -Scientific Advisory Committee, Israel Cancer Research Fund, 1991-Present -Investigational New Drug Committee, National Cancer Institute of Canada -Member, Scientific Advisory Board, Les Laboratoires Aeterna (Aeterna Zentaris). 1999- Present -Member, Scientific Advisory Board, Thallion Pharmaceuticals Inc(Ecopia) 2005-Present -Member, Scientific Advisory Board, Sopherion Therapeutics, 2004-Present -Member, Scientific Advisory Board, Immunotec Inc., 2006-Present 5. Invited Presentations and Workshops 2006 Toronto, Ontario Cancer Institute, Seminar- Title “Refining and enhancing our view of molecular targets in cancer therapeutics”. 2006 Atlanta, ASCO, presented poster, title “Developmental Therapeutics: Cytotoxic Chemotherpay” 2006 Montreal, Joint conference held by the Weizmann Institute of Science and the McGill Cancer Centre, McIntyre Bldg, Palmer Auditorium, invited speaker, title “New Therapeutics: The Long and Winding Road”. 2006 Montreal, Palais des Congres, SYM39 Special Symposium: Molecular targeted therapy for cancer, speaker, Talk: "Molecular diagnostics in the development and the use of novel cancer therapeutics". 2006 Como, Italy –"International Workshop on Anthracycline Cardiotoxicity", speaker, title: "Cardiac safety of liposomal anthracyclines" 2007 McGill - 1st Expert Care Plan Initiative Workshop, The McGill Educational Initiative on Interprofessional Collaboration: Partnerships for Patient and Family- centered Practice. March 24 2007 Hôtel du Lac Carling, Québec – 27ieme Session de Formation Continue de l’ABCQ, invited speaker, title “Cancer Biomarkers- a great hope not yet fulfilled”. May 18 15
  16. 16. Department of Oncology Annual Report 2006/2007 2007 Chicago, ASCO, presented poster, abstract title: “Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy”. June 3 2007 Gananoque, ON – Queen’s University Cancer Research Inst. Annual Retreat, Invited speaker, title: “Chemoprevention and chemotherapy resistance: the importance of context”. June 11 6. Other Activities 2006 Chair, Search & selection committee, Eric Flanders Professor of Palliative Care Medicine Nicole Beauchemin 1. Summary of New and Ongoing Research Modifiers of colon cancer. Dr. Philippe Gros, Dept. of Biochemistry, McGill University. Induction of colon tumors in eIF4-BP3-deficient mice. Dr. Nahum Sonenberg. Dept. of Biochemistry, McGill University. Evaluation of colon cancer pathology in transgenic and knockout mice. Dr. Victoria Marcus, MUHC pathologist, McGill University. Investigation into the insulin resistance phenotype of Ceacam1-/- mice. Dr. Emile Lévy, Centre de Recherche, Hôpital Ste-Justine, Montréal. Investigations into the altered fat metabolism in Ceacam1-/- mice. Dr. Roland Savard. Dept. of Biologie, UQAM, Montréal. Immunology and infections with MHV of Ceacam1-/- mice. Dr. Lucie Lamontagne. Dept. of Biologie, UQAM, Montréal. The role in CEACAM1 in activated T lymphocytes. Dr. André Veillette, IRCM Montréal. The role of the tyrosine phosphatase SHP-1 in metabolism. Dr. André Marette, Centre de Recherche du CHUL. Ste-Foy Qué. Association of CEACAM1 with Tyrosine phosphatases. Dr. Bjorn Obrink, Dept. of Cell Biology, Karolinska Institute, Stockholm, Sweden. Development of an endothelial-specific transgenic mouse model for CEACAM1, Dr. Christoph Wagener, Dept. of Clinical Biochemistry, Univ. of Hamburg, Hamburg, Germany. Mice Resistant to mouse hepatitis viral infections. Dr. Kathryn V. Holmes, Dept. of Microbiology, Univ. of Colorado, Denver, CO. 16
  17. 17. Department of Oncology Annual Report 2006/2007 Analyses of brain-tropism of MHV in Ceacam1-/- targeted mice. Dr. Susan Weiss, Department of Microbiology, Univ. of Pennsylvania School of Medicine, Philadelphia, USA. Development of a Humanized CEACAM1-targeted mouse. Dr. Scott Gray-Owen, Dept. of Microbiology, Univ. of Toronto, Toronto, Canada. The functions of CEACAM1 in platelets. Dr. Denise Jackson. Austin Research Institute. Melbourne Australia. The role of CEACAM1 in dendritic cells. Drs. Robert Kammerer and Wolfgang Zimmerman. Klinikum der Universität München. Munich Germany. The role of CEACAM1 in insulin receptor signaling. Dr. Sonia M. Najjar. Medical College of Ohio. Toledo Ohio. The role of CEACAM1 in graft versus host disease. Dr. Marcel R.M. van den Brink. Memorial Sloan-Kettering Cancer Center. New York. N.Y. The role of CEACAM1 in immune responses of M cells. Drs. H. Kiyono and O. Igarashi. Institute of Medical Science, The University of Tokyo. Tokyo, Japan. The role of CEACAM1 in lung tissue. Dr. Bob Scholte, Cell Biology Dept. Eramus University Medical Centre, Rotterdam, The Netherlands. 2. Research grants (new and ongoing) Canadian Institutes for Health Research, CEACAM1 signaling in epithelial cell adhesion and motility, 2003-2007, $128,664/yr PI: Nicole Beauchemin Cancer Research Society Inc., Involvement of mouse biliary glycoproteins (CEACAM1) in tumor development and metastasis, 2005-07, $60,000./yr, PI: Nicole Beauchemin National Cancer Institute of Canada, CEACAM1 in colon cancer progression, 2005-08, $113,050./yr, PI: Nicole Beauchemin Miriam and Saul Goldberg Innovative Research, Genetic control to susceptibility of carcinogen-induced colon cancer, 2007-08, $ 15,000./yr, PI: Philippe Gros, co-PI: Nicole Beauchemin Canadian Institutes for Health Research, Metabolic functions of the PTPase SHP-1 in insulin target tissues, $123,030./yr, 2007-2012, (co-PI Nicole Beauchemin with André Marette & Kathryn Siminovitch) National Cancer Institute of Canada, Genetic control to susceptibility of carcinogen- induced colon cancer, 2007-2010, $123,000./yr, PI: Philippe Gros, co-PI: Nicole Beauchemin Canadian Institutes for Health Research, CEACAM1 as a regulator of normal and tumor angiogenesis, 2007-2012, PI: Nicole Beauchemin, pending, 17
  18. 18. Department of Oncology Annual Report 2006/2007 Cancer Research Society Inc., Involvement of mouse biliary glycoproteins (CEACAM1) in tumor development and metastasis, 2007-09, PI: Nicole Beauchemin, pending 3. Construction of major facilities or major equipment grants and their impact Renewal application for the McGill Cancer Centre infrastructure grant with Dr. Michel Tremblay, FRSQ, 2007-2011, $400,000./yr. This budget is the major source of funding of the Centre for its research operations. 4. Major University Committees Chairperson of the Cancer Centre Safety committee since Jan. 2004-2006. Member of the Cancer Centre Recruitment committee since 2004-2006. Chairperson of the McGill Cancer Centre Advisory Committee, since Jan. 2005. Member of an Ad Hoc Faculty Postgraduate Promotions Review committee, Faculty of Medicine, since November 2003-2006. Member of the Faculty Promotions Committee, Faculty of Medicine, 2 meetings per year since June 2003-2006. Member of the Dept. of Oncology Promotions Committee, 2 meetings per year since 2006. Member of the Faculty of Medicine Admissions committee, 1 week/year of interviews of potential Medicine students, 2007-. Member of MUHC Lutte Contre le Cancer (Colorectal) team (2006-..). Presentation at McGill University Grantsmanship meeting (2007-…). 5. Research Training: undergraduate students, graduate students, postdocs/fellows Undergraduate Students Atta Goudarzi (Biochemistry), Summer 2006 Sarah Leblanc (Biochemistry), Winter 2007 Graduate Students Nelly Leung (Biochemistry), 2000-present, Ph.D. (expected 2008) Renée Atallah (Biochemistry), 2003-2006, M. Sc. (2006) Anne-Marie Charbonneau-Allard (Biochemistry), 2005-present, M.Sc. (2007) 18
  19. 19. Department of Oncology Annual Report 2006/2007 Sarah Leblanc 2007-present, M.Sc. (2009) Post-Doctoral Fellows Anne-Laure Nouvion, Ph.D. Institute de Chimie-Biologie, Lyon, 2006-2010 Graduate students on whose supervisory committees I currently serve. RAC Nelly Leung, Dept. of Biochemistry 2001- RAC Melanie Chagnon, Dept. of Biochemistry 2003- RAC Renée Atallah, Dept. of Biochemistry 2004-2006 RAC Anne-Marie Charbonneau-Allard, 2005-2007 RAC Patrick Fok, Montreal Neurological Institute, 2004-2006 RAC Valérie Hudon, Dept. of Biochemistry, 2004- RAC Ghada Kurban, Dept. Biochemistry, 2004- RAC for Charles Meunier, Dept. of Biochemistry, 2006- RAC Malika Oubaha, IRCM, 2007- RAC Kataryna Jesien, Dept. of Medicine, IRCM, 2007- GAC Shun Li, Royal Victoria Hospital, student of Dr. P. Brodt, 2007- GAC for Sami Bouahia, Dept. of Biochemistry, May 2007- GAC for David Grote, Dept. of Biochemistry, April 2007- GAC for Alana Nguyen, Dept. of Biochemistry, April 2007- Ph.D. Oral Defense for John Lee, Dept. of Biochemistry, Dec. 2006. Ph.D. Oral Defense of Josée Laganière, Dept. of Biochemistry, Feb. 13, 2007. Pro-Dean on Ph.D. Defense of Kristin Joy Stewart, Dept. of Physics, May 2007. 6. Scientific Reviews: Editorial Boards and Journal Reviews Journal Review Nature Reviews Immunology Oncogene X 4 7. Research Advisory Work for National and International Organizations Panel Member 19
  20. 20. Department of Oncology Annual Report 2006/2007 Member of the “Prix de la Recherche” committee for ACFAS, 2004-06 Canadian Institutes for Health Research Palliative Care committee, 2005- National Cancer Institute of Canada, Panel J, 2006- Ad hoc reviews for grant panel Canadian Institutes for Health Research, 2006 NSERC, 2006, 2007 8. Conference Organization Organizer of the McGill Cancer Centre seminar series 2005- Co-organizer of the Angiogenesis-Metastasis Research Group 2006-: meeting once/month of 15-20 research groups from the Montreal region interested in these topics. 9. Invited Presentations and Workshops (National and International) La tyrosine phosphatase SHP-1 régule négativement l’homéostasie du glucose. 5e Symposium sur la physiopathologie du tube digestif. Sherbrooke Qc, June 2006. CEACAM1, more than a gut feeling. Weissman Institute-Cancer Centre first international meeting, Montreal, Qc. Sept. 2006. CEACAM1: Role in progression of colon cancer and its progression through angiogenesis. Dept. of Oncology Retreat, Montreal, Qc. Nov. 2006. CEACAM1: from progression of colon cancer to integrity of blood vessels. Invited talk in the Dept. of Microbiology, University of Colorado, Denver CO, USA, Dec. 15 2006. CEACAM1 as a regular of normal and tumor angiogenesis. Angiogenesis and Metastasis Research Group. January 2007. CEACAM1: entre l’adhésion cellulaire, le cancer du côlon et l’angiogénèse. Invited talk at the Centre de Recherches de l’Hotel Dieu, Québec, Qc, May 25 2007. 10. Peer-Reviewed Abstracts Novel CEACAM1 splice variants expressed by murine small intestinal epithelium. Kazutaka Terahara, Osamu Igarashi, Masato Yoshida, Tomonori Nochi, Yoshiyuki Gotoh, Fumihiro Taguchi, Nicole Beauchemin, Hiroshi Kiyono. IUBMB International Congress of Biochemistry and Molecular Biology. Dec. 2006, Kyoto, Japan. Detection of a novel locus on chromosome 3 responsible for susceptibility to colon cancer (CRC) in mice. Charles Meunier, Anny Fortin, Nicole Beauchemin and Philippe Gros. Canadian Genetic Disease Network meeting, St-Sauveur Qc, April 2007. 20
  21. 21. Department of Oncology Annual Report 2006/2007 Hyperproliferative Corneal Epithelium Expresses Proinflammatory Molecules That Recruit Neutrophils to the Cornea of corn1 Mice. A. M. Verdoni, N. Beauchemin, A. Ikeda, S. Ikeda. AVRO meeting, April 2007. Detection of a novel locus on chromosome 3 responsible for susceptibility to colon cancer (CRC) in mice. Charles Meunier, Anny Fortin, Nicole Beauchemin and Philippe Gros. Human Genome meeting, Montreal, Qc. May 2007. CEACAM1 in tumor angiogenesis of genetically-modified mouse models. Anne-Laure Nouvion, Claire Turbide, Valérie Breton, Andrea Horst, Christoph Wagener, William J. Muller and Nicole Beauchemin. 17th Annual CEA Workshop, Los Angeles California, 2007. Ceacam1 and Apc Cooperate Through Wnt Signaling in Mouse Intestinal Tumor Progression. Nelly Leung, Claire Turbide, Brinda Balanchandra, Victoria Marcus, Nada Jabado and Nicole Beauchemin. 17th Annual CEA Workshop, Los Angeles California, 2007. 11. Involvement in the community Member of the Institutional Review Board at the Ville-Marie Breast Clinic. Meetings once/month for evaluation of clinical trial protocols. (2004-…). Actively involved in speaking engagements to volunteers of the Canadian Cancer Society. Sept. 26, 2006: meeting of volunteers and conference, Montreal. March 22, 2007: shooting of a 2 h video interview for publicity campaigns of CCS. March 29, 2007: conference at Place Desjardins for Daffodil Day. April 11, 2007: meeting the press for unveiling of Cancer Statistics. Performed 7 television interviews. April 18, 2007: conference for volunteers in Sherbrooke Qc. May 18, 2007: 1 h interview at Radio-Ville Marie, Montreal, Qc. Philip Branton 1. Summary of New and Ongoing Research Thomas Dobner (Hamburg) - adenovirus E4orf6 protein Jose Teodoro (MCC) - adenovirus E4orf4 protein 2. Research grants (new and ongoing) a. Mechanism of Oncogene Transformation by Human Adenoviruses (Main applicant), Canadian Institutes of Health Research (CIHR), from 04/2006 to 03/2009, $630,000 21
  22. 22. Department of Oncology Annual Report 2006/2007 b. Mechanism of Action of the Adenovirus Death Protein E4orf4 (Main applicant), National Cancer Institute of Canada, from 04/2004 to 03/2009, $750,000 c. Mechanism of oncogenic transformation by human adenovirus of p53 (Main applicant), Canadian Institutes of Health Research (CIHR), from 04/2002 to 03/2008, $412,500 d. FRSQ special funds to support Quebec CIHR director, Fonds de la Recherche en Santé du Québec (FRSQ), from 04/2001 to 03/2008, $300,000 3. Research Training: undergraduate students, graduate students, postdocs/fellows 1. Mui, Melissa (PhD) 2. Cheng, Chi Ying (PhD) 3. Binda, Olivier (PhD awarded 2007) 4. Miron, Marie-Joelle (PhD awarded 2007) 5. Li, Suiyang (Post-doc) 6. Blanchette, Paola (Post-doc) 4. Scientific Reviews: Editorial Boards and Journal Reviews Ad hoc reviews for several journals 5. Research Advisory Work for National and International Organizations 1. 2006-present Chair, International Advisory Board, University Hospital Network, University of Toronto 2. 2006-present Member, Board of Directors, National Cancer Institute of Canada (NCIC) 3. 2005-present Vice Chair, Board of the Canadian Cancer Research Alliance 4. 2004-present Member, Alberta Cancer Board, Advisory Committee on Research 5. 2003-present Member, Board of the Canadian Tobacco Control Research Initiative (CTCRI) 6. 2002-present Chair, Research Action Group of the Canadian Strategy for Cancer Control 7. 2002-present Member, Governing Council, WHO-International Agency for Cancer Research (Lyon, France) 8. 2001-present Member, Advisory Committee on Research, Canadian Alliance of Provincial Cancer Agencies (CAPCA) 9. 2001-present Member, Board of the Canadian Breast Cancer Research Alliance (CBCRA) 10. 2006- present Consultant, Terry Fox Research Institute 22
  23. 23. Department of Oncology Annual Report 2006/2007 6. Conference Organization Organizer and session chair, DNA Tumor Virus Meeting July 11-14, 2006. The Salk Institute, La Jolla CA 7. Invited Presentations and Workshops (National and International) BRANTON, P.E. 2006. Mechanism of action of the adenovirus death protein. FASEB Summer Research Conferences (Protein Phosphatases), Snowmass, CO, July 15-20. (plenary talk, p47). 8. Peer-Reviewed Abstracts 1. Binda, O., J.-S. Roy and P.E. Branton. 2006. RBP1 family proteins exhibit SUMOylation-dependent transcriptional repression and induce cell growth inhibition reminiscent of senescence. Signal Transduction Meeting, Banff Alberta, March 3-7, 2005. (poster presentation, p.8) 2. Roopchand, D.E., M. Mui, M. Gentry, R. Hallberg, J. Vogel and P. E. Branton. 2006. Human adenovirus E4orf4 protein induces premature mitotic arrest by a PP2A- dependent mechanism leading to cell death in Saccharomyces cerevisiae. Signal Transduction Meeting, Banff Alberta, March 3-7, 2005. (plenary talk). 3. Blanchette, P., P. Groitl, T. Dobner and P.E. Branton. 2006. The major functions of E4orf6bduring adenoviral infection are achieved through its associated E3 ligase activity. DNA Tumor Virus Meeting 2006. The Salk Institute, La Jolla CA. July 11-14. (plenary talk, p58). 4. Miron, M.-J, P. Blanchette, P. Groitl, T. Dobner and P.E. Branton. 2006. Localization and functions of adenovirus E4orf4 virus mutants. DNA Tumor Virus Meeting 2006. The Salk Institute, La Jolla CA. July 11-14. (plenary talk, p67). 5. Branton, P.E. 2006. Mechanism of action of the adenovirus death protein. FASEB Summer Research Conferences (Protein Phosphatases), Snowmass, CO, July 15-20. (plenary talk, p47). 9. Involvement in the community None other than science councils Terry Chow 1. Summary of New and Ongoing Research Molecular and Genetic Analysis of Avascular Necrosis - publication: Mohammad Amin Kerachian, Edward j Harvey, Denis Cournoyer, Terry Y.K. Chow, Chantal Seguin. Avascular Necrosis of the Femoral Head: Vascular hypotheses. 2006. Endothelium 13:237-244. 23
  24. 24. Department of Oncology Annual Report 2006/2007 2. Scientific Reviews: Editorial Boards and Journal Reviews Journal Reviews Molecular Cancer Therapeutics International Journal of Cancer 3. Research Advisory Work for National and International Organizations INSERM (France) External Panel of Expert 2006 4. Involvement in the community Member of the Board of Directors, Montreal Chinese Hospital Member of the User's Committee, Montreal Chinese Hospital S. Robin Cohen 1. Research Grants Improving Quality of Life and Informing Social Policy in Palliative Care. Infrastructure Funding to form a National Palliative Care Research Team. Robin Cohen (PI), Co Investigators: Allard P, Band P, Blood P, Chochinov H, Courneya K, Daneault S, Deschamps M, Dumont S, Fiset V, Fournier L, Fyles G, Gagnon P, Graham I, Gratton J, Kristjanson L, Lawlor P, Leis A, Logan J, Marchand R, Neron S, Nikoletti S, Poirier L, Porock D, Poulson J, Viola R, Wilson K, and others. National Cancer Institute of Canada - #010281 01/2000–12/2002, $60,000/year Renewed, 01/2003 – 06/2007; $88,000/year; $88,000/year; $88,000/year Quality of Life for Palliative Care Patients and Their Family Caregivers Robin Cohen (PI), Co-investigators: Brown S, Fiset V, Fyles G, Kristjanson L, Leis A, Porterfield P, Viola R. National Cancer Institute of Canada - #012201 Renewal. 07/2001 – 06/2006 $555,659 Strategic Training Program in Palliative Care Cancer Research. Robin Cohen (PI), Co Investigators: M Aubin, S Dumont, L Fillion, D Blondeau, P Gagnon, P Allard, F Fothergill-Bourbonnais, P Hall, P Dobkin, N Mayo, K Wilson. Canadian Institutes of Health Research/National Cancer Institute of Canada - #STI-63286, 04/2003 – 03/2009, $1,800,000 Prognostic value of clinical correlates of cancer cachexia: A prospective multicenter, population-based study. A Vigano PI, Co-investigators: Baracos, V, S Robin Cohen, Dalzell MA, Franco E, Macdonald N, Morais J, Thirlwell M, Canadian Institutes of Health Research - #122338 06/2004 – 05/2007 $200,644 A multidisciplinary cancer pain research network to improve the classification, assessment, and management of difficult cancer pain problems. P.I.s: N.A. Hagen , R.L. Fainsinger, P.M. Brasher, Co-investigators: Pereira, JL, Moulin, D Cahill CM, Cohen SR, Cummings- OLinyk GG, Canadian Institutes of Health Research- # 129697, 2004 – 2009 $1,363,586 24
  25. 25. Department of Oncology Annual Report 2006/2007 GRISIM: Groupe de recherche interuniversitaire en soins infirmiers de Montréal P.I.s: Celeste Johnston and Nicole Richard, Co-investigator Cohen SR and many others FRSQ/Newton Foundation/MSSS, 04/2004 – 03/2008, $2,000,000 Evaluation of group remedial exercises for chronic breast cancer related lymphedema. P.I. Diane St. Pierre, Co-Investigators: Towers A, Cohen SR, Collet JP, Dalzell M National Cancer Institute of Canada - CCS Feasibility Grant, 2005 – 2006 $34,380 Quality of life in cancer patients admitted to an acute palliative care unit and their caregivers: a prospective study of self-report and proxy-for-patient ratings P.I.: Jennifer Jones, Co-Investigators: Cohen SR, Rodin GM, Zimmerman C, McPherson CNational Cancer Institute of Canada – CCS Research Grant for New Investigators, 2005 – 2006, $55,371; 2006 – 2007, $56,956; 2007 – 2008, $62,614 Measuring the quality of end-of-life care provided in inpatient health care settings, P.I. Kelli Stajduhar, Co-investigator Cohen SR, others, Michael Smith Foundation for Health Research HSPRSN Research Operating Grant, 05/2006 – 04/2008, $99,796 An evaluation of Canada’s compassionate care benefit from a family caregiver’s perspective, Co- P.I.s: A Williams and V Crooks, Co-investigators Stajduhar K, Allan D, Cohen SR , Brazil K. Canadian Institutes of Health Research (CIHR) 09/2006 – 08/2009, $169,729 Safety in home care: Perspectives from clients, family members, caregivers, and providers. P.I: Lang A, Co-investigators: Cohen SR, Easty AC, Lachance JA, Germain D, Stajduhar KI, Williams AM Canadian Institutes of Health Research 04/2007- 03/2010, $53, 237/year Family caregiving at the end of life: A women’s health issue, PI Koop P, Co- investigators: deJong-Berg MA, Cohen SR, Williams A, Stadjuhar K, Allan D, Canadian Foundation for Women’s Health, 01/06/2006 –31/05/2007, $8,035 Réduire l'incidence de la morbidité du membre supérieur suite aux traitements pour le cancer du sein : développement et évaluation d'un projet pilote en kinésiologie, PI: Towers A, Co-investigators: Letellier M, St. Pierre D, Cohen SR, Fondation Québécoise du Cancer (no grant number), 06/2006 – 06/2007, $15,000 Family caregiving in palliative and end-of-life care: A new emerging team, Robin Cohen (Co-PI with Kelli I Stajduhar), Co-investigators: Chappell, N, Koop, P, Williams, A, Heyland, D. Canadian Institutes of Health Research- #129692, 2004 – 2009, $1,361,361 T.I.P.S: Tele-homecare in palliation study. Co-investigators: Larry Librach, Co- applicants: Cohen SR, Abernathy T, GoldSmith, C, Jadad, C, Kirshen, A, Librach L, Thabane L (P.I.: A. Stern, McMaster) Ontario Ministry of Health Primary Health Care Transition Fund 04/2004 – 04/2006, $933,900 25
  26. 26. Department of Oncology Annual Report 2006/2007 2. Teaching and Research Training PhD Students and Postdocs Shuling Chen Spirituality & Palliative Care in Chinese Canadians, Education (Ph.D. Thesis Committee Member), Ph.D. in progress Oct. 2002 – present. Anita Mehta Family caregivers of palliative care patients at home: The pain management process, Nursing, Ph.D. in progress, Sept. 2003 – present. (Maternity leave July-Dec 2006), -NCIC Studentship Marianne Olivier- d’Avignon Development of a needs profile for siblings of terminally ill children, Social Work, U. Laval. Co- supervisor with Serge Dumont, Ph.D., May 2006- present Lisa Chan The experience of end-of life-care on an end-stage medical in-patient unit, Nursing, Ph.D., Sept.2005-present. Melissa Henry, Ph.D. (Psychology) Meaning Making Intervention for women with newly diagnosed advanced ovarian cancer, Oncology , Postdoctoral Fellowship, April 2006- present Mary Rykov, Ph.D. (Adult Education) The impact of music therapy on patients and families on palliative care units, Oncology, Postdoctoral Fellowship, July 2006- present, NCIC Postdoctoral Fellowship. Réjeanne Dupuis, Psychology,York University Co-supervisor with Paul Ritvo, Ph.D., Sept. 2006- present. Andreea Iancu, M.D. Palliative Medicine Fellow, Cancer Pain Classification System, Nov.2005-Oct.2006 McGill Courses Winter 2006 , NUR2 705 A required course for the interdisciplinary Psychosocial Oncology Option in the Faculty of Graduate Studies and Research, Palliative Care in Cancer. April 20, 2006, Oncology Interdisciplinary Journal Club, Staff member responsible for discussion of student presentation of RCT. 3. Scientific Reviews: Editorial Boards and Journal Reviews Editorial Boards Journal of Palliative Care, 2004- present American Journal of Hospice and Palliative Care, 2004- present Ad Hoc Reviews Journal of Palliative Care, 1996, 97, 98, 99, 2000, 2001, 2002, 2004, 2005, 2006 26
  27. 27. Department of Oncology Annual Report 2006/2007 Palliative Medicine, 1996, 97, 98, 99, 2001, 2006 Journal of Pain and Symptom Management, 2001, 2002, 2006 Quality of Life Research, 2006, 2007 4. Research Advisory Work for National and International Organizations National Cancer Institute of Canada , Clinical Fellowships Peer Review Committee, July 1-2006-June 30-2007 Ad Hoc Reviewer: Fonds de recherche en santé du Québec 1997, 1998, 2006 Committees McGill Department of Oncology Clinical Trials Operations, Supportive Care Section, Member, 1999 –present Canadian Hospice Palliative Care Association, Research Advisor, March 2003 – present Wellness Centre, Jewish General Hospital, Research Advisory Board, Member, February 2005- present VON Canada-University of Ottawa Bereavement Think Tank, Member, April 2005- present 5. Congress and Workshop Organization 16th International Congress on Care of the Terminally Ill, Montreal, September 25-28, 2006, Executive and Organizing Committee: Determining Congress content and schedule Sole Organizer of Research Program. Chair of Research Abstract Review Committee. Chair all Research Fora 17th International Congress on Care of the Terminally Ill, Montreal, September 22-26, 2008, Executive and Organizing Committee: Determining Congress content and schedule Sole Organizer of Research Program. Chair of Research Abstract Review Committee. Chair all Research Fora 27
  28. 28. Department of Oncology Annual Report 2006/2007 6. Invited Presentations and Workshops (National and International) and Peer Reviewed Abstracts Williams A, Crooks V, Stadjuhar K, Cohen SR, Allan D. Women's Caregiving Work at End-Of-Life: An Evaluation of Canada's Compassionate Care Benefit. Ontario Women's Health Council Conference "Enhancing Women's Health Research", April, 2006, Ottawa, Ont. Cohen SR, Brown KS, Fyles G, Lachance J, Leis A, Viola R, Porterfield, P. The Quality of Life of Family Caregivers of People with Cancer at the End of Life. Canadian Association of Psychosocial Oncology Annual Conference: Psychosocial Risks and Consequences Across the Lifespan, Montreal, May 3-6, 2006 Koop PM, deJong-Berg MA, Williams A, Cohen SR, Allan D, Stajduhar K. Defining Caregiver Respite in End-of-Life Care: A Systematic Literature Review: Canadian Association of Psychosocial Oncology Annual Conference: Psychosocial Risks and Consequences Across the Lifespan, Montreal, May 3-6, 2006. Koop PM, deJong-Berg MA, Williams A, Cohen SR, Allan D, Stajduhar K. Defining Caregiver Respite in End-of-Life Care: A Systematic Literature Review. UICC World Cancer Congress, Washington, DC, July 8-12, 2006. Allan,DE, Heyland DK, Homer S, Gafni A, Frank C, Stajduhar KI, and Cohen SR. Prognostic awareness, satisfaction with quality of care, and resource utilization at end of life. Canadian Association for Health Services and Policy Research, Vancouver, BC, September 17-19, 2006. Cohen SR, Fyles G, Leis A, Viola R, Porterfield P, Lachance J, Brown KS. Family care quality of life relationship to carer optimism, sense of self-efficacy, and sense of preparedness to provide care to terminally ill people with cancer International Psycho- Oncology Society Conference, Venice, Italy, Oct.18-22, 2006.Psycho-Oncology 2006, 15 (Supp2);S207 *Thibodeau-Jarry N, Cohen SR. Content validity and acceptability of patient and family caregiver quality of life: Instruments for an end stage medical population 16th International Congress on the Care of the Terminally Ill, Montreal, Quebec, Sept.26-29, 2006. Journal of Palliative Care 2006, 22; 247. *Taylor G, Carpentier S, Cohen SR. Quality of life assessment in palliative care: How do family caregivers interpret the items? 16th International Congress on the Care of the Terminally Ill, Montreal, Quebec, Sept.26-29, 2006, Journal of Palliative Care 2006, 22; 240. *Carpentier S, Taylor G, Cohen SR. Quality of life assessment in palliative care: How do patients interpret the items? 16th International Congress on the Care of the Terminally Ill, Montreal, Quebec, Sept.26-29, 2006, Journal of Palliative Care 2006, 22, 237. Rose PA, Cohen SR, Amsel R. Pressure ulcer (PU) risk assessment in the critically ill. National Pressure Ulcer Advisory Panel biennial conference, San Antonio, Texas, February 9-10, 2007. 28
  29. 29. Department of Oncology Annual Report 2006/2007 7. Hospital Activities Encompassed within responsibilities with McGill. McGill Executive Committee, Palliative Care McGill, Member, 1995 – present Division of Palliative Care, Oncology, Research Director, April 1996 – present Palliative Care McGill Education Committee, Member, 1998 – present Oncology, Member, Interdisciplinary Postgraduate Training Committee, Sept. 2002 – present Oncology, Member, Psychosocial Oncology Program, Sept. 2002 – present School of Nursing, Student Standing and Promotions Committee, Member, Dec. 2002 – April 2004 Sept.2005-present School of Nursing, Ph.D. Supervisors Committee, Member, January 2001 – present MUHC Palliative Care Service Divisional Meeting, Member, January 2003 – present Cancer Nutrition and Rehabilitation Program Steering Committee , Member, June 2005- present Eric Flanders Professor in Palliative Care Medicine Selection Advisory Committee, Member, June 2005-present Faculty of Medicine Student Research and Summer Research Bursary Committee, Member, 2006, 2007 Justine Farley 1. Conference Organization Program Committee for the 2006 and 2008 International Congress on Care of the Terminally Il, Montreal Responsable de la « Rencontre avec Serge Daneault « Souffrance et médecine », le 12 mai 2007, à Dorval, organisé avec Le programme de soins palliatifs du CH de Verdun 2. Invited Presentations and Workshops (National and International) Comité de programmation, 16e congrès international sur les soins aux malades en phase terminale, 26 au 29 septembre 2006. Membre du comité organisateur, Euthanasie et suicide assisté, conférence Derouin- Renaud, Montréal, le 3 mai 2006. La sédation palliative, l’art et la science de la médecine, Hôpital Ste-Anne-de-Bellevue, le 5 mai 2006. 29
  30. 30. Department of Oncology Annual Report 2006/2007 Présidente d’atelier, Soins palliatifs, Congrès international de droit médical, Toulouse, France, 7 août 2006. L’insuffisance cardiaque terminale, Symposium annuel, Société québécoise de l’insuffisance cardiaque, St-Sauveur, le 29 septembre 2006. Approches simples en soins palliatifs, 2e journée scientifique annuelle de l’établissement d’Argenteuil, le 27 octobre 2006. Chemotherapy at the End of Life, Therapeutic Issues Day, CH St.Mary, le 23 novembre 2006. Les soins palliatifs d’un milieu à l’autre, un défi d’arrimage. En collaboration avec Dr Geneviève Dechênes, Colloque de la direction de lutte contre le cancer, Montréal, le 1er décembre 2006. 3. Hospital Activities Full-time clinician in Palliative Care within the Oncology Department and the Family Medicine Departement Chef du service de soins palliatifs Présidente du comité d’évaluation du CMDP du CH de St.Mary, jusqu’au 31 décembre 2006 Membre invité à l’Exécutif du CMDP, jusqu’au 31 décembre 2006 Membre du Quality and Risk Management Coordinating Committee, jusqu’au 31 décembre 2006 Membre du comité de gestion du Cancer Care Program Membre du comité de gestion de la qualité du Cancer Care Program: préparation de la visite 2006 du Conseil canadien d’agrément des services de santé (CCHSA) Présidente du Comité des finances du Fond d’Oncologie 4. National and International Commitees Membre du comité de gestion du Cancer Care Program Membre du comité de gestion de la qualité du Cancer Care Program: préparation de la visite 2006 du Conseil canadien d’agrément des services de santé (CCHSA) Présidente du Comité des finances du Fond d’Oncologie Présidente du Réseau de soins palliatifs du Québec depuis avril 2006 Responsable de la journée de réflexion sur le Suicide assisté, journée pré-congrès du Réseau de soins palliatifs: le 23 avril 2006 30
  31. 31. Department of Oncology Annual Report 2006/2007 Membre délégué au Conseil d’administration de l’Association canadienne de soins palliatifs Membre au Organizational Development Committee Membre du Best Practices and Quality Care Working Group, Canadian Strategy on Palliative and End-of-Life Care, Health Canada Membre du comité aviseur pour le Projet Hospice and End-of-life Care, du Conseil canadien d’agrément des services de santé Membre du Comité sur l’évaluation des médicaments anticancéreux, comité du Conseil du médicament, de mai 2005 à ce jour. Visiteur pour l’accréditation des centres d’oncologie par la Direction du programme de lutte contre le cancer, 2006 William Foulkes 1. Research grants (new and ongoing) Title of Grant: BRCA1 splice variants and the breast cancer risk: novel approaches using nanobiology Agency: Canadian Breast Cancer Research Alliance, IDEA grant Dollars Awarded: CDN $97,380 total Dates of Approved Project: July 1, 2006 through June 30, 2007 Name of P.I.: WD Foulkes The goal of this project is to determine whether currently undiscovered splice variants of BRCA1 could contribute to risk of breast cancer in the general population. Title of Grant: Toward the biological treatment of BRCA1-related breast cancer: EGF, EGFR and tyrosine kinase inhibitors Agency: Canadian Breast Cancer Research Alliance, Operating grant Dollars Awarded: CDN $423,000 total Dates of Approved Project: July 1, 2006 through June 30, 2009 Name of P.I.: WD Foulkes List of Co-Applicants: Tarek Bismar, Raquel Aloyz, Parviz Ghadirian 31
  32. 32. Department of Oncology Annual Report 2006/2007 The major goal of this study is to determine if alterations in receptor tyrosine kinases play a role in hereditary breast cancer. Title of Grant: The 3D telomeric signature(s) of DCIS Agency: Susan G Komen BrCa Foundation, Operating grant Dollars Awarded: US$249,805 total Dates of Approved Project: May 1, 2006 through April 31, 2009 Name of P.I: Sabine Mai List of Co-Applicants: WD Foulkes In this project, we wish to find out whether telomere dysfunction is an early event in DCIS. Title of Grant: BRCA1, CDC4, Cyclin E, and Chromosomal Instability in Breast Cancer Agency: Canadian Breast Cancer Research Alliance, Operating grant Dollars Awarded: CDN$ 430,000 total Dates of Approved Project: April 1, 2005 through March 30, 2008 Name of P.I.: WD Foulkes List of Co-Applicants: Sabine Mai, Torsten Nielsen The major goal of this project is to explore the cyclin E axis in BRCA1-related breast cancer. Title of Grant: Defining aggressive phenotype of prostate cancer using a multiplex of 12 gene model Agency: Prostate Cancer Research Foundation of Canada (PCRFC), Operating grant Dollars Awarded: CDN$ 60,000 Dates of Approved Project: Mar 1, 2005 through Feb 28, 2007 Name of P.I.:Tarek Bismar List of Co-Applicants: WD Foulkes, M. A Rubin The major goal of this study is to investigate the value of 12 gene model expression in localized prostate cancer in predicting cancer recurrence and cancer specific death. The 12 gene model was identified through gene expression profile and proteomic study of more than 1500 different gene of the prostate gland. 32
  33. 33. Department of Oncology Annual Report 2006/2007 Title of Grant: Risk factor analysis of hereditary breast and ovarian cancer Agency:Canadian Breast Cancer Research Alliance, Operating grant Dollars Awarded: CDN$ 1,250,000 Dates of Approved Project: July 1, 2004 through June 30, 2009 Name of P.I.: Steven Narod List of Co-Applicants: WD Foulkes (receives no funding on this grant), P Ghadirian, A Eisen The aim of this project is to identify and quantify the role of risk modifiers in BRCA1/2 mutation carriers. Title of Grant: Programme de recherché en appui aux politiques de santé en génétique dans un souci de qualité, d'efficience et de bien-être social Agency: Canadian Institutes of Health Research Dollars Awarded: CDN$ 1,000,000 Dates of Approved Project: Jan 1, 2003 through Dec 31, 2007 Name of P.I.: Renaldo N Batista List of Co-Applicants: WD Foulkes (receives no funding on this grant), I Blancquaert G Cleret de Langavant, D Gaudet, B Godard, N Laflamme, A Marcoux, F Rousseau The major goals of this project are the establishment of acknowledge network for the development of health policy in genetics from the academic world and clinical world, and governmental agencies. Title of Grant: The Genetic of Prostate Cancer: The ICPCG Study Agency: National Institutes of Health (NIH) Dollars Awarded: US$ 2,097,089 total Dates of Approved Project: Sept 1, 2002 through Aug 31, 2006 Name of P.I.: William B Isaacs List of Co-Applicants: WD Foulkes, J Epstein, A Partin, D Easton, R Eeles, L Maehle et al. The goal of this study includes combined epidemiological, mutation analysis and linkage studies of thousands of men with hereditary, familial or sporadic prostate cancer. 33
  34. 34. Department of Oncology Annual Report 2006/2007 2. Research Training: undergraduate students, graduate students, postdocs/fellows Graduate Students Supervised Name: Tayma Khalil (Raquel Aloyz: co-supervisor) Department: Human Genetics Years: 2005- Degree: MSc Topic: CDC4 in hereditary breast cancer Postdoctoral Trainees Name: Ahmet Yilmaz Department: Human Genetics Years: 2006- current Topic: CHEK2 and breast and prostate cancer in Ashkenazi Jews Advisor, M.Sc. And Ph.D Graduate Supervisory Committees Name: Andrea Karin Lawrance, MSc Thesis: Diet, folate and polyps in models of murine intestinal cancer Supervisor: Dr. Rima Rozen (Department of Human Genetics) Date: May 2001-current 3. Research Advisory Work for National and International Organizations Scientific Advisory Committee, Breast Cancer Family Registry (NIH), 2006- Promotion review (to Associate Attending Physician), Memorial Sloan-Kettering Hospital, November 2006 Promotion review (to Associate Member), Memorial Sloan-Kettering Cancer Center, November 2006 Canadian Breast Cancer Research Initiative, IDEA grant panel, 2006 4. Conference Organization Second International Symposium on Hereditary Breast and Ovarian Cancer, Montreal Oct 17-19, 2007. (www.odon.ca/brca/). Co-sponsored by the Program in Cancer Genetics and the Hereditary Breast and Ovarian Cancer Foundation (www.hboc.ca). Role: Scientific Director of Conference. 34
  35. 35. Department of Oncology Annual Report 2006/2007 5. Invited Presentations and Workshops (National and International) a) International August 16, 2006 Title: Recent advances in understanding of the inherited susceptibility to cancers of the prostate, pancreas, stomach and colorectum, Australian Ovarian Cancer Study and the Family Cancer Clinics of Australia, Couran Cove Island Resort, Stradbroke Island, Australia August 18, 2006 Title: Hereditary breast cancer: from pathology to treatment and beyond, Australian Ovarian Cancer Study and the Family Cancer Clinics of Australia, Couran Cove Island Resort, Stradbroke Island, Australia October 28, 2006 Title: Breakthrough treatments for BRCA1 and BRCA2 mutation carriers, 10th Annual Cincinnati Comprehensive Breast Cancer Conference, Cutting Edge Strategies in Breast Cancer: The next decade, Cincinnati, OH, USA November 9, 2006 Title: Hereditary breast cancer: from pathology to treatment and beyond, Cancer Colloquia IV: Cell and Molecular Biology of Breast Cancer, University of St-Andrews, St-Andrews, Scotland b) National June 15, 2006 Title: Genetics and Breast Cancer: An update, Toronto Breast Cancer Symposium 2006, Metro Toronto Convention Center, Toronto, Ontario 6. Hospital Activities Teaching Hereditary Breast Cancer (Surgical Residents) October 2006, (1 hour teaching session surgical residents, RVH) 35
  36. 36. Department of Oncology Annual Report 2006/2007 Eduardo Franco 1. Summary of New and Ongoing Research As PI: • Antioxidant nutrients among a Brazilian population (A Giuliano, E Franco [co-Pis], J Marshall, D Roe, L Villa, N Craft) National Institutes of Health (NCI Grant # RO1CA81310, approx. $1.3 million [US$ 870,000], 2000-03; renewed 2004-07, approx. $1.2 million). • Biomarkers of cervical cancer risk (E Franco, F Coutlée, G Matlashewski, M. Pollak, M Roger) Canadian Institutes of Health Research (CIHR grant #MOP-42532, $418,119, 2000-04; renewed 2005-08, $313,587). • Efficacy trial of HPV versus Pap testing for screening cervical cancer precursors (E Franco, F Coutlée, S Ratnam, S Walter, E Duarte, I Rodrigues, R Rajan, M Steben). Canadian Institutes of Health Research (CIHR grant #MCT-54063, $1,071,837, 2002-07). • PAP Cytology Screening Failure: Influences of the Patient, Physician, and Laboratory (E Franco, E Duarte-Franco, F Coutlée, A Ferenczy, P Ghadirian, M Dawes, M Deschamps, P Drouin). Canadian Institutes of Health Research (grants # IHS-61108, $48,545, 2002-03 and MOP-64454 $312,945, 2003-07). • HPV infection and transmission among couples through heterosexual activity (the HITCH cohort) (E Franco, F Coutlée, J Hanley, P Tellier). Canadian Institutes of Health Research (grant# 68893, $546,544, 2004-09). • CIHR Team in HPV infection and associated diseases (E Franco, F Coutlée [co-PIs], M Roger, G Matlashewski, P Brassard, Z Rosberger, A Al-Moustafa, J Archambault, P Davies, B Duval, R Rajan). Canadian Institutes of Health Research (grant #83320, $2,546,941, 2007-13). As Co-investigator: • Characterization of the human papillomavirus infection among a population of Inuit women in Québec. (P Brassard, E Franco, F Coutlée, M Roger). Canadian Institutes of Health Research (CIHR grant #MOP57749, $496,752, 2002-07). • Economic evaluation of population screening for cervical cancer using HPV testing in Canada (R Rajan, E Franco, J Penrod). National Cancer Institute of Canada (grant # 014033, $186,139, 2003-07). • Development and validation of new statistical methods for modeling intermediate events in survival analysis (M Abrahamowicz, A Ciampi, A Benedetti, E Franco, M Klein, L Pilote, R Platt, J Siemiatycki) Canadian Institutes of Health Research (grant# ATF66665, $158,263, 2004-06; renewed $54,787, 2006-07). 36
  37. 37. Department of Oncology Annual Report 2006/2007 • Prognostic value of clinical correlates of cancer cachexia: A prospective, multicenter, population-based study (A Vigano, V Baracos, S Cohen, MA Dalzell, E Franco, N Macdonald, S Thirlwell). Canadian Institutes of Health Research (grant# MOP- 67043, $211,925, 2004-07). • CIHR training program in applied Oral Health Research (J Feine, P Allison, E Franco, W Fraser, M Frenette, D Grenier, A Kolta, G Lavigne, J Lund, M Mckee). Canadian Institutes of Health Research (grant #QTA-68723, $1.76M, July 2004 – June 2010). • Molecular analysis of HPV infection in precancerous and cancerous lesions of the uterine cervix (F Coutlée, E Franco, G Matlashewski). Canadian Institutes of Health Research (grant# MOP-67155, $289,371, 2004-07). • The life course approach to the aetiology of squamous cell carcinoma in the upper aerodigestive tract (P Allison, E Franco, R Fuhrer, G Humphris, B Nicolau, A Sacker). Canadian Institutes of Health Research (grant #69062, $434,063, October 2004 – September 2007). • The psychosocial impact of Pap versus HPV testing on Canadian women screened for cervical cancer (Z Rosberger, P DiDio, E Duarte, E Franco, B Knauper, MH Mayrand). Canadian Institutes of Health Research (grant# pending, $160,000, 2005- 08). • A randomized controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer (P Allison, LJ Edgar, J Feine, E Franco, B Nicolau, R Rajan). Canadian Institutes of Health Research (grant #MCT-75475, $471,139, April 2005 – March 2009). • A randomised controlled evaluation of HPV testing for cervical cancer screening (A Coldman, P Davies, R Martin, J Matsic, D Van Niekerk, G Ogilvie, T Ehlen, G Stuart, E Franco, S Peacock, M Krajden), Canadian Institutes of Health Research (grant #TBA, $6,268,935, 2006-13). • The life course approach to studying the etiology of head and neck cancer: HeNCe life study (B Nicolau, P Allison, R Burk, F Coutlée, E Franco, G Humphris, J O’Loughlin, A Sacker, N Schlecht), Canadian Institutes of Health Research (grant #TBA, $478,236, 2006-10). Industry support (non-peer-reviewed unrestricted grants) (amounts in Canadian dollars) • Support for the Canadian Cervical Cancer Screening Trial (Merck-Frosst Co., $75,000, 2004-07). • Support for the HPV infection and transmission among couples through heterosexual activity (the HITCH cohort) (Merck-Frosst Co., $472,072, 2006-09) 37
  38. 38. Department of Oncology Annual Report 2006/2007 International Activities: • PI of the Ludwig-McGill Cohort Study of the Natural History of HPV Infection and Cervical Neoplasia. • Member, Nominating Committee, International Epidemiological Association (2005-) • Chair, World Congress Advisory Committee, International Epidemiological Association (2005-) 2. Research grants (new and ongoing) See above. 3. Research Training: undergraduate students, graduate students, postdocs/fellows • H Trottier. Epidemiology of cervical cancer. Postdoctoral fellow, Department of Oncology, McGill University, Montreal, 2004-07. • M-H Mayrand. Efficacy trial of HPV testing in cervical cancer screening. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-06 (FRSQ and NCIC scholarships). • A Spence. Determinants of cervical cancer screening failure. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2001-07. • T Dang-Tan. Childhood cancer surveillance. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-06 (CIHR scholarship). • CV Atwood. Determinants of cervical cancer screening. MSc thesis, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-06. • S Lau. Natural history of ASCUS cervical cytological abnormalities. Ongoing MSc research (part-time student), Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-07. • A. Burchell. Behavioural determinants of HPV transmissibility. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2003-08 (Tomlinson and NCIC scholarships). • A De Pokomandy. Anal intraepithelial neoplasia in HIV-infected men. Ongoing MSc research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2005-07. 38
  39. 39. Department of Oncology Annual Report 2006/2007 • L Tomita. Diet, serum micronutrients and risk of cervical neoplasia. Ongoing PhD research (jointly), Departamento de Nutrição, Faculdade de Saúde Pública, Universidade de São Paulo, Brazil, Summer 2006. 4. Scientific Reviews: Editorial Boards and Journal Reviews International peer-review journals • Cancer Detection and Prevention (Editorial Board, from February 2001) • Cancer Epidemiology, Biomarkers and Prevention (Editorial Board, 1995-2007) • Epidemiology (Editorial Board, 1993-2008) • Oral Diseases (Editorial Board, from March 2005) • Public Library of Science (PLoS) – Medicine (Editorial Board, 2004-) Other • HPV Today (Scientific Committee Member, 2002-) • Salud Pública de México (Editorial Board, 2004-) Manuscript reviews (total of 41 from June 1, 2006 to May 31, 2007) Canadian Journal of Public Health (1), Canadian Medical Association Journal (1), Cancer Causes and Control (1), Cancer Detection and Prevention (4), Cancer Epidemiology, Biomarkers and Prevention (4), Cancer Research (4), Epidemiology (2), Chronic Diseases in Canada (1), Epidemiology & Infection (1), Gynecologic Oncology (1), International Journal of Cancer (6), Journal of General Virology (1), Journal of Infectious Diseases (2), Journal of the National Cancer Institute (1), Lancet (1), Oral Diseases (3), Oral Oncology (1), Proceedings of the National Academy of Sciences (1), Public Library of Science-Medicine (2), Sexually Transmitted Diseases (1), Tissue Antigens (1), Virus Genes (1) Grant reviews (internal): 13 • RO1 grants for NIH: 9 • NIH Intramural proposals: 4 39
  40. 40. Department of Oncology Annual Report 2006/2007 Faculty evaluations • Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, USA (2006). • National Cancer Institute, Division of Cancer Epidemiology and Genetics, National Institutes of Health, Rockville, USA (2007). • University of Arizona Prevention Center, Tucson, USA (2006). • University of Montreal, Departments of Nutrition and Microbiology and Immunology, Faculty of Medicine, Canada (2006). 5. Research Advisory Work for National and International Organizations National • National Cancer Institute of Canada, Toronto: Member, Awards-in-Excellence Committee (2005-07). • National Cancer Institute of Canada, Toronto: Member, Nominating Committee (2005-). • Member, Environment Cancer Fund Advisory Board, Cancer Research Society, Toronto, Canada (2006-) • Clinical Medicine and Basic Biology Working Group, National Cancer Institute of Canada’s Prevention Initiative, Toronto, Canada (2006-07) International • National Cancer Institute, National Institutes of Health, Bethesda, USA: Member (2006), Site Review Committees for the intramural research program of the Hormonal, Reproductive and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics. • National Institutes of Health, Epidemiology & Disease Control-2 Study Section (renamed Epidemiology of Cancer [EPIC] panel in 2003), Bethesda, USA: Member (2002-07). • Consultant, University of Arizona Male HPV Cohort Study, University of Arizona, Tucson, USA (2003-). • Clinical Medicine and Basic Biology Working Group, National Cancer Institute of Canada’s Prevention Initiative, Toronto, Canada (2006-07) • Member, Scientific Advisory Board, The HPV Foundation, New York, USA (2004-). 40
  41. 41. Department of Oncology Annual Report 2006/2007 • Member, Ad hoc Meeting of experts on surveillance of HPV-associated disease in the Americas, Pan American Health Organization, Washington, USA (October 2006). • Member, External Advisory Committee, Cancer Control and Population Sciences, University of Puerto Rico Comprehensive Cancer Center, San Juan, USA (2007-). 6. Conference Organization • Member, Steering Committee, “1st Global Congress on World Religions after September 11”, Montreal, Canada (September 2006). • Member, International Scientific Committee, 24th International Papillomavirus Conference and Clinical Workshop (IPCCW) to be held in Beijing, China (November 2007). • Member, Candidacy Planning Committee, World Cancer Congress of the Union Internationale Contre le Cancer, Montreal, Canada (winning bid for 2012). • Member, Local Organizing Committee, International Papillomavirus Conference, Montreal, Canada (2010). • Member, 60th Anniversary Cancer Research Conference Program Committee, National Cancer Institute of Canada, Toronto (2007) 7. Invited Presentations and Workshops (National and International) National (18) • “Principles of Clinical Research in Oncology: Grand Rounds Lecture to the Oncology Training Program, McGill University Health Centre, Montreal General Hospital, Montreal, Canada (September 29, 2006). • “HPV Vaccination: A New Paradigm in Cervical Cancer Prevention” Seminar to the Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada (October 16, 2006). • “Expected impact of HPV vaccination on cervical cancer screening practices” Seminar to the Merck-Frosst HPV Club, Montreal Museum of Fine Arts, Montreal, Canada (October 25, 2006). • Chair and Speaker “L’impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du cancer du col utérin” in the Symposium “Dépistage du cancer du col utérin: une approche en pleine mutation”, 10es Journées annuelles de santé publique, Montréal, Canada (October 27, 2006). 41
  42. 42. Department of Oncology Annual Report 2006/2007 • Chair and Speaker, “Prevention of cervical cancer: New paradigms”, Lecture in Workshop “Human Papilloma Virus Vaccination - A New Cervical Cancer Control Strategy”, 6th World Congress on Vaccines and Immunization, Montreal, Canada (November 8, 2006). • "Molecular epidemiology of HPV infection and cervical cancer" Lecture at the Sainte-Justine Hospital, Montreal, Canada (November 10, 2006). • “Human Papillomavirus: Truth or Fiction”, Plenary lecture, Continuing Medical Education Conference “Eradicating Cervical Cancer”, Cancer Care Manitoba, Winnipeg, Canada (November 17, 2006). • “Marrying HPV vaccines to screening”, Plenary lecture, Continuing Medical Education Conference “Eradicating Cervical Cancer”, Cancer Care Manitoba, Winnipeg, Canada (November 17, 2006). • “Impact of HPV vaccination on screening practices” Lecture, HPV and Cervical Cancer Prevention Summit: New Opportunities for Partnerships and Prevention, Montreal, Canada (November 28, 2006). • “The expected impact of HPV vaccination on cervical cancer screening practices” Lecture to the Cervical Cancer Screening Management Staff, Cancer Care Ontario, Toronto, Canada (December 14, 2006). • “HPV Vaccination in Cervical Cancer Prevention: Evidence and Implications” Lecture at the Division of Preventive Oncology, Cancer Care Ontario, Toronto, Canada (December 14, 2006). • “Changing Landscapes in HPV and Cervical Cancer Prevention and Screening” Lecture at the CityWide Grand Rounds, Women's Hospital, University of Toronto, Toronto, Canada (December 15, 2006). • "HPV Vaccination in cervical cancer prevention: promises & perils" Lecture given in the Symposium Challenges in Obstetrics & Gynecology, Gelber Conference Centre, Montreal, Canada (March 16, 2007). • Co-Chair and Speaker, “Impact of Vaccination on Screening Programs: An Opportunity” Lecture in Session “Implementation of the HPV Vaccine: Gaps in Knowledge and Opportunities”, 7th Annual Continuing Professional Development Meeting, Society of Gynecologic Oncologists of Canada, Toronto, Canada (April 27, 2007). • “Epidemiology of Genital HPV Infection and Cancer of the Cervix”, Lecture, 2nd Annual Gynaecologic Cancer Update Day: “Emerging Trends in Cervical Cancer”, Stratford, Canada (May 11, 2007). 42
  43. 43. Department of Oncology Annual Report 2006/2007 • “Issues in planning screening in the era of HPV vaccination” Lecture, 2nd Annual Gynaecologic Cancer Update Day: “Emerging Trends in Cervical Cancer”, Stratford, Canada (May 11, 2007). • “Changing Landscapes in HPV and Cervical Cancer Prevention and Screening” Lecture given to the Institut du Cancer de Montreal, Centre de Recherche du CHUM- Hôpital Notre-Dame, Montreal, Canada (May 16, 2007). • “The implications of a new paradigm in cervical cancer prevention” Plenary lecture, XXXII Réunion des Registres des pays de Langue Latine, Montreal, Canada (May 17, 2007). International (45) • “Inovação na Prevenção do Câncer Cervical” Plenary lecture and panel discussion, 6th Congresso Brasileiro de Citologia Clinica, Curitiba, Brazil (June 5, 2006). • “O uso do teste HPV no rastreamento do câncer de colo uterino: Promessas e obstáculos”, Plenary lecture, 6th Congresso Brasileiro de Citologia Clinica, Curitiba, Brazil (June 6, 2006). • “História Natural do HPV e do Câncer do Colo Uterino: O que resta a descobrir?” Plenary lecture, 6th Congresso Brasileiro de Citologia Clinica, Curitiba, Brazil (June 7, 2006). • Chair, Plenary session “Recognizing and Solving Public Health Problems with Epidemiology: The Example of Cervical Cancer Control”, lecture: “A timeline for public health research in cervical cancer etiology and prevention” Congress of Epidemiology 2006 (sponsored by 18 societies), Seattle, USA (June 22, 2006). • Chair, Contributed paper session “Innovation in Cancer Screening and Prevention” Congress of Epidemiology 2006 (sponsored by 18 societies), Seattle, USA (June 22, 2006). • Nominator’s Introduction during Awards Ceremony to introduce Dr. Nubia Muñoz as Outstanding Epidemiologist of 2006. Congress of Epidemiology 2006 (sponsored by 18 societies), Seattle, USA (June 23, 2006). • “Impacto das vacinas contra o HPV no rastreio do cancro cervico-uterino” Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Português de Oncologia do Porto, Porto, Portugal (June 27, 2006). • “Infeccões como agentes etiologicos no cancro: o papel das vacinas” Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Português de Oncologia do Porto, Porto, Portugal (June 27, 2006). 43
  44. 44. Department of Oncology Annual Report 2006/2007 • “Vacinação Contra a Infecção pelo HPV: O novo Paradigma da Prevenção do Cancro do Colo do Útero” Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Nacional de Saúde, Lisbon, Portugal (June 29, 2006). • “O Impacto da Vacinação Contra o HPV no Rastreio do Cancro de Colo do Útero” Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Nacional de Saúde, Lisbon, Portugal (June 29, 2006). • Chair and Speaker, “Human Papillomavirus Infection and Cervical Cancer: Promises and Perils in Prevention Research” Symposium: “Infection And Cancer: Prospects For Prevention”, UICC World Cancer Congress, Washington, USA (July 9, 2006). • Chair and Speaker, “Global burden of cervical cancer and HPV-associated diseases”, Symposium " Advances With Vaccines for the Prevention of Cervical Cancer and Other HPV-Related Diseases", UICC World Cancer Congress, Washington, USA (July 10, 2006). • “New approaches in cervical cancer screening” Lecture in Session: “Cervical Cancer Screening: Strategies for Developing Countries”, UICC World Cancer Congress, Washington, USA (July 10, 2006). • “HPV vaccination as a promising new strategy for cervical cancer prevention”, 37th Annual Conference, New Zealand Society of Cytology, Napier, New Zealand (August 24, 2006). • “Efficacy of HPV testing in cervical cancer screening”, 37th Annual Conference, New Zealand Society of Cytology, Napier, New Zealand (August 24, 2006). • “The impact of HPV vaccination on cervical cancer screening”, 37th Annual Conference, New Zealand Society of Cytology, Napier, New Zealand (August 24, 2006). • “Assessing new cancer screening technologies: The tyranny of evidence-based medicine”, 37th Annual Conference, New Zealand Society of Cytology, Napier, New Zealand (August 25, 2006). • “Epidemiology of HPV and CIN” Plenary lecture, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 1, 2006). • Chairperson, Clinical Workshop Session 1, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 1, 2006). • Speaker, Session “Handling HPV vaccines and screening”, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 3, 2006). • Co-Chair, Session PS10 “Preventive vaccines: models”, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 4, 2006). 44
  45. 45. Department of Oncology Annual Report 2006/2007 • Speaker, Meet the Experts Session: Putting Science into Practice, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 5, 2006). • “O Valor da Vacinação contra o HPV na Prevenção do Câncer de Colo do Útero” Opening keynote lecture, Congresso Internacional de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre, Brazil (October 4, 2006). • “Controle do Câncer de Colo do Útero na Prática Diária: O impacto da Vacinação contra o HPV” Plenary lecture, Congresso Internacional de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre, Brazil (October 5, 2006). • “Grau de Evidência no Diagnóstico de Lesões Cervicais” Roundtable presentation, Congresso Internacional de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre, Brazil (October 6, 2006). • “Historia natural de las infecciones por virus del papiloma humano”, Plenary lecture, 1st Congress of the Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 3, 2006). • “Tendencias actuales para detección de VPH”, Plenary lecture, 1st Congress of the Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 3, 2006). • Chair and Speaker, Session on Vaccines, “La eficacia de vacunas bivalentes”, 1st Congress of the Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 4, 2006). • “Concluding Remarks: The Road Ahead”, Closing Plenary Lecture, 1st Congress of the Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 4, 2006). • “Planning Cervical Cancer Screening in the Era of HPV Vaccines”, Symposium lecture, Frontiers in Cancer Prevention Research Conference, American Association for Cancer Research, Boston, USA (November 15, 2006). • “Epidemiologia da Infecção por HPV”, Plenary lecture, Conferencia sobre Patologia Cervical 2006, Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006). • “Rastreio do Cancro do Colo do Útero na Era Pós-Vacina”, Plenary lecture, Conferencia sobre Patologia Cervical 2006, Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006). • “Questões relacionadas com a implementação da vacina: O que sabemos?”, Plenary lecture, Conferencia sobre Patologia Cervical 2006, Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006). 45
  46. 46. Department of Oncology Annual Report 2006/2007 • “Molecular epidemiology of HPV infection: new approaches” Roundtable presentation, 1st International Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and Epidemiology. São Paulo, Brazil (November 30, 2006). • Co-Chair and Discussant, Session “Childhood cancer – HPV and retinoblastoma: is there a relationship?”, 1st International Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and Epidemiology. São Paulo, Brazil (December 1, 2006). • “Distal and proximal causal agents in cancer: Reconciling social and molecular epidemiology” Lecture, 1st International Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and Epidemiology. São Paulo, Brazil (December 1, 2006). • “Vacuna VPH 16 & 18: una estrategia viable para la prevención del Ca. Cu.” Plenary lecture, Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (March 30, 2007). • “Impacto esperado de la vacunacion sobre los programas de deteccion” Plenary lecture, Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (March 30, 2007). • “La vacuna candidata de GSK VPH 16 & 18 contra Ca. Cu. Preguntas y respuestas” Plenary lecture, Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (March 30, 2007). • “Promises and perils in the changing landscape of cervical cancer prevention” Lecture given to the Department of Obstetrics and Gynecology, School of Medicine, Universidad de Puerto Rico, San Juan, USA (May 8, 2007). • “New directions in epidemiologic research on HPV and cancer” Symposium lecture, 3rd Puerto Rican Conference of Public Health, San Juan, Puerto Rico, USA (May 9, 2007). • “Bivalent HPV prophylactic vaccine: Efficacy for the prevention of cervical cancer” Plenary Lecture, International HPV Clinical Training and Scientific Workshop, Medellin, Colombia (May 24, 2007). • “Gaps in knowledge and research priorities for the prevention of cervical cancer in Latin American countries” Plenary Lecture, International HPV Clinical Training and Scientific Workshop, Medellin, Colombia (May 25, 2007). • “Impact of HPV vaccination in cervical cancer screening programs” Plenary Lecture, International HPV Clinical Training and Scientific Workshop, Medellin, Colombia (May 26, 2007). 46
  47. 47. Department of Oncology Annual Report 2006/2007 • “HPV vaccination and screening: The need for synergy in cervical cancer prevention strategies” Plenary lecture, Congress “Prevenzione hpv: dalla ricerca traslazionale al vaccini: Nuove strategie e nuovi paradigmi di prevenzione sul territorio regionale”, Rome, Italy (May 31, 2007). 8. Peer-Reviewed Abstracts • de Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EF, Coutlée F. HPV-16, 18, 31, 45 viral loads in anal intra-epithelial lesions in HIV-seropositive men. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006. • Gagnon S, Hankins C, Pourreaux K, Franco E, The Canadian Women’s HIV Study Group, Coutlée F. Polymorphism of the capsid L1 gene is not a determinant of persistence of HPV-52 infection in HIV-seropositive women. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006. • Mayrand MH(§), Mahmud SM, Franco EL, Hanley J. Design, ethical and statistical challenges when studying the performance of new screening tests for cervical cancer. 23rd International Biometric Conference, Montreal, Canada, July 2006. • Burchell AN(§), Hanley J, Richardson H, Mahmud SM, Trottier H, Tellier PP, Coutlée F, Franco EL. Use of stochastic computer simulation and maximum likelihood methods to estimate sexual transmissibility of human papillomavirus infection. 23rd International Biometric Conference, Montreal, Canada, July 2006. • Trottier H(§), Schaffer A, Koushik A, Duarte-Franco E, Coutlée F, Pollak M, Franco EL. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Trottier H(§), Mahmud S, Prado J, Rohan TE, Villa LL, Franco EL. Duration of type- specific HPV infection: Results from the Ludwig-McGill cohort study. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus (HPV) 16/18 vaccine on the burden of cervical disease in the UK. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Trevisan A, Schlecht NF, Ferreira S, Sichero L, Ferenczy A, Duarte-Franco E, Franco EL, Villa LL. Correlation between viral load measured by real-time and low- stringency PCR testing of cervical specimens. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. 47
  48. 48. Department of Oncology Annual Report 2006/2007 • Sichero L, Ferreira S, Trottier H, Ferenczy A, Franco EL, Villa LL. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Sénécal M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Foucart S, Brisson M, Mansi JA. Psychosocial impact of cervical screening and condyloma: an epidemiological study (pisces). 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Mayrand MH(§), Duarte-Franco E, Rodrigues I, Walter SD, Coutlée F , Ratnam S, Franco EL. Comparison of Pap and hpv testing strategies for screening high-grade cervical cancer precursors: Results from the Canadian Cervical Cancer Screening Trial (CCCaST). 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • De Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Côté P, MacLeod J, Allaire G, Fontaine J, Trépanier JM, Franco EL, Coutlée F. Human Papillomavirus 16, 18, 31, 45 viral loads and grade of anal intraepithelial neoplasia in HIV-infected men. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Tomita LY(§), Carneiro LC, Villa LL, Franco EL, Cardoso MA. Serum micronutrients in relation to human papillomavirus infection in Brazilian women: Preliminary results. 1st World Congress of Public Health Nutrition, Barcelona, Spain, September 2006. • Tomita LY(§), D´Almeida V, Longatto-Filho A, Villa LL, Franco EL, Cardoso MA. Higher homocysteine and lower serum levels of alpha-tocopherol are risk factors for cervical dysplasia in women living in São Paulo, Brazil. Frontiers in Cancer Prevention Research Conference, American Association for Cancer Research, Boston, USA, November, 2006. • Mahmud S, Turner D, Franco E, Aprikian A. Meta-analysis of the effects of aspirin, NSAID and acetaminophen use on prostate cancer risk. Poster presentation. Canadian Society of Epidemiology and Biostatistics. Calgary, Canada, May 2007. 9. Involvement in continuing education activities (mostly during speaking engagements in various conferences, nationally and internationally). 10. Involvement in the community The following are in addition to activities outlined above: 48
  49. 49. Department of Oncology Annual Report 2006/2007 Consultancies to the private sector: • Technical Advisory Committee, Glaxo SmithKline Pharmaceuticals, Brussels, Belgium: HPV vaccines (1998-). • Technical Advisory Committee, Innovus, Inc., Burlington, Canada: Economic models of the natural history of cervical cancer (2000-). • Consultant, Merck-Frosst, Canada: Burden of HPV-associated diseases (2004-). • Consultant, GenProbe Inc. USA: HPV diagnostics (2007) • Consultant, Roche Molecular Systems: cervical cancer screening (2007). University service (McGill University) • Member, Management Committee, Department of Oncology (2001-) • Member, Committee on Joint Residency Training in Oncology, Faculty of Medicine (1994-present). • Chair, Faculty Promotion Sub-committees, Department of Oncology (2003-present). • Chair, Student Funding Committee, Department of Epidemiology and Biostatistics (2005-). Carolyn Freeman 1. Summary of New and Ongoing Research Current Research Interests Clinical research in paediatric tumours especially brain tumours and in soft tissue sarcomas in adults. Use of radio-sensitising and biological agents in pediatric brain tumours. Development of new radiotherapy treatment techniques. Evaluation of new radiotherapy technologies. 2. Research grants (new and ongoing) 2001 – 2007, National Childhood Cancer Foundation (NCCF): Co-Chair CNS Strategy Committee, Children’s Oncology Group (N.H.) Salary award ~ $20,000.00/yr. National Cancer Institute of Canada (With Seuntjens, J. (PI), Verhaegen, F., Shenouda, G. and Podgorsak, E.) Monte Carlo-based modulated electron beam inverse treatment planning and delivery. $61,960/year operating grant 49
  50. 50. Department of Oncology Annual Report 2006/2007 3. Construction of major facilities or major equipment grants As Head of Radiation Oncology at the MUHC, I have been responsible for the acquisition of major new equipment including cone beam imaging for brachytherapy and Tomotherapy. 4. Research Training: undergraduate students, graduate students, postdocs/fellows I have supervised research projects of medical students and trainees in Radiation Oncology at McGill and at the U of M. 5. Scientific Reviews: Editorial Boards and Journal Reviews Editorial Boards 1987 - present Associate Editor, International Journal of Radiation Oncology, Biology and Physics 1999 – 2006, Member, Editorial Board, Journal of Neuro-Oncology 2004 – present, Member, Editorial Board, Pediatric Blood and Cancer Ad hoc Reviews Frequent: (8-10 each /year) International Journal of Radiation Oncology Biology Physics Pediatric Blood and Cancer Occasional: (1-3 each/year) American Journal of Pediatric Hematology Oncology Cancer Clinical Oncology European Journal of Cancer Expert Opinion in Oncology International Journal of Pediatric Hematology-Oncology Journal of Clinical Oncology Journal of Neuro-Oncology Radiotherapy and Oncology Very occasional: (0-1 each /year) Annals of the RCPSC 50
  51. 51. Department of Oncology Annual Report 2006/2007 Canadian Medical Association Journal Clinical and Investigative Medicine Expert Review of Neuro-therapeutics Journal of the Canadian Association of Radiologists Lancet Oncology Radiology GRANT REVIEWS Panel Member: 2007 Member, Clinical trial/companion studies panel. Ontario Institute for Cancer Research Ad Hoc Grant Reviews 2006 Ad hoc reviewer, National Cancer Institute of Canada 2006 Ad hoc reviewer, Cancer Research UK x 2 2006 Ad hoc reviewer, Pediatric Brain Tumor Consortium NIH 6. Invited Presentations and Workshops (National and International) “Radiotherapy for pediatric brainstem gliomas.” Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, May 2006. Guest lecture. “The Children’s Oncology Group CNS studies: strategy, progress and plans for the future.” Annual meeting of the National Cancer Research Institute. Birmingham, England, October 2006. Canadian Radiation Oncology Resident review course. “Paediatric CNS Tumours.” Montreal, January 2007. 7. Hospital Activities Administrative work McGill 51

×